ZELTIQ Aesthetics (ZLTQ) 10-K 15 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 10, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	Zeltiq Aesthetics Inc
Entity Central Index Key	1,415,336
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Common Stock, Shares Outstanding		39,310,213
Entity Public Float			$ 953,437,429

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS:
Cash and cash equivalents	$ 35,710	$ 28,649
Short-term investments	12,867	16,286
Accounts receivable, net	33,359	21,472
Inventory	28,095	15,536
Prepaid expenses and other current assets	11,771	7,060
Total current assets	121,802	89,003
Long-term investments	3,490	4,805
Restricted cash	452	560
Property and equipment, net	6,969	3,724
Intangible asset, net	5,092	5,780
Long-term deferred tax assets	40,475	0
Other assets	547	33
Total assets	178,827	103,905
CURRENT LIABILITIES:
Accounts payable	10,903	5,824
Accrued and other current liabilities	34,691	21,450
Deferred revenue	7,682	5,069
Current portion of capital lease obligations	124	120
Total current liabilities	53,400	32,463
Long-term deferred revenue	226	622
Long-term capital lease obligations, less current portion	138	262
Other non-current liabilities	761	39
Total liabilities	$ 54,525	$ 33,386
Commitments and contingencies
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.01 par value: 50,000,000 shares authorized and no shares issued and outstanding at December 31, 2015, and December 31, 2014	$ 0	$ 0
Common stock, $0.001 par value: 500,000,000 shares authorized at December 31, 2015, and December 31, 2014; 39,217,630 and 38,123,998 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively	43	42
Additional paid-in capital	215,621	202,701
Accumulated other comprehensive loss	(1,636)	(696)
Accumulated deficit	(89,726)	(131,528)
Total stockholders’ equity	124,302	70,519
Total liabilities and stockholders’ equity	$ 178,827	$ 103,905

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value (dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	39,217,630	38,123,998
Common stock, shares outstanding	39,217,630	38,123,998

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenue	$ 255,416	$ 174,478	$ 111,626
Cost of revenue	74,375	50,064	34,189
Gross profit	181,041	124,414	77,437
Operating expenses:
Research and development	22,909	18,196	17,090
Sales and marketing	125,458	83,579	63,185
General and administrative	28,980	20,515	16,510
Total operating expenses	177,347	122,290	96,785
Income (loss) from operations	3,694	2,124	(19,348)
Interest income, net	58	63	80
Other income (expense), net	(420)	(425)	103
Income (loss) before income taxes	3,332	1,762	(19,165)
Provision for (benefit from) income taxes	(38,470)	231	140
Net income (loss)	$ 41,802	$ 1,531	$ (19,305)
Basic net income (loss) per share:
Net income (loss) per share, basic (dollars per share)	$ 1.08	$ 0.04	$ (0.53)
Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic (shares)	38,754,643	37,563,590	36,209,051
Diluted net income (loss) per share:
Net income (loss) per share, diluted (dollars per share)	$ 1.02	$ 0.04	$ (0.53)
Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted (shares)	40,795,646	40,996,972	36,209,051

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 41,802	$ 1,531	$ (19,305)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(925)	(767)	77
Changes in unrealized gains (losses) on available-for-sale securities	(15)	(16)	2
Other comprehensive income (loss), net of tax	(940)	(783)	79
Comprehensive income (loss)	$ 40,862	$ 748	$ (19,226)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012	$ 72,580	$ 39	$ 186,287	$ 8	$ (113,754)
Balance, shares at Dec. 31, 2012		35,852,105
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options	$ 2,647	$ 2	2,645
Issuance of common stock upon exercise of stock options, shares	791,198	791,198
Issuance of common stock in connection with ESPP	$ 791		791
Issuance of common stock in connection with ESPP, shares		188,467
Proceeds for repayment of notes receivable from a stockholder	0
Issuance of common stock upon vesting of RSUs	0
Issuance of common stock upon vesting of RSUs, shares		292,265
Tax payments related to shares withheld for vested restricted stock units	$ (876)		(876)
Common stock traded for employee tax obligation (shares)	(85,661)	(85,661)
Stock-based compensation	$ 6,660		6,660
Change in unrealized gain (loss) on marketable securities, net of tax	2			2
Currency translation adjustments, net of tax	77			77
Net income (loss)	(19,305)				(19,305)
Balance at Dec. 31, 2013	62,576	$ 41	195,507	87	(133,059)
Balance, shares at Dec. 31, 2013		37,038,374
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options	$ 2,787	$ 1	2,786
Issuance of common stock upon exercise of stock options, shares	569,283	569,283
Issuance of common stock in connection with ESPP	$ 1,532		1,532
Issuance of common stock in connection with ESPP, shares		103,089
Issuance of common stock upon vesting of RSUs	0
Issuance of common stock upon vesting of RSUs, shares		724,400
Tax payments related to shares withheld for vested restricted stock units	$ (6,594)		(6,594)
Common stock traded for employee tax obligation (shares)	(311,368)	(311,148)
Stock-based compensation	$ 9,383		9,383
Tax benefit from employee stock plans			87
Change in unrealized gain (loss) on marketable securities, net of tax	(16)			(16)
Currency translation adjustments, net of tax	(767)			(767)
Net income (loss)	1,531				1,531
Balance at Dec. 31, 2014	70,519	$ 42	202,701	(696)	(131,528)
Balance, shares at Dec. 31, 2014		38,123,998
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options	$ 4,136	$ 1	4,135
Issuance of common stock upon exercise of stock options, shares	608,931	608,931
Issuance of common stock in connection with ESPP	$ 2,492		2,492
Issuance of common stock in connection with ESPP, shares		108,552
Issuance of common stock upon vesting of RSUs	0
Issuance of common stock upon vesting of RSUs, shares		635,256
Tax payments related to shares withheld for vested restricted stock units	$ (8,283)		(8,283)
Common stock traded for employee tax obligation (shares)	(259,107)	(259,107)
Stock-based compensation	$ 13,219		13,219
Tax benefit from employee stock plans	1,357		1,357
Change in unrealized gain (loss) on marketable securities, net of tax	(15)			(15)
Currency translation adjustments, net of tax	(925)			(925)
Net income (loss)	41,802				41,802
Balance at Dec. 31, 2015	$ 124,302	$ 43	$ 215,621	$ (1,636)	$ (89,726)
Balance, shares at Dec. 31, 2015		39,217,630

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net income (loss)	$ 41,802	$ 1,531	$ (19,305)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2,423	1,824	1,729
Stock-based compensation	13,219	9,383	6,660
Deferred income tax (benefit) expense	(40,405)	(19)	19
Amortization of investment premium, net	89	221	343
Provision for (recovery of) doubtful accounts receivable	859	324	(12)
Provision for excess and obsolete inventory	270	853	262
Loss on disposal and write-off of property and equipment	6	46	2
Changes in operating assets and liabilities:
Accounts receivable	(12,920)	(11,219)	(3,064)
Inventory	(12,941)	(6,898)	2,225
Prepaid expenses and other assets	(5,338)	(2,419)	(693)
Deferred revenue	2,254	2,908	267
Accounts payable, accrued and other liabilities	18,425	2,609	7,486
Net cash provided by (used in) operating activities	7,743	(856)	(4,081)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Purchase of investments	(16,024)	(13,444)	(31,591)
Proceeds from sale of investments	0	1,000	11,143
Proceeds from maturity of investments	20,654	21,393	25,528
Purchase of property and equipment	(4,279)	(2,340)	(834)
Change in restricted cash	94	(252)	138
Net cash provided by investing activities	445	6,357	4,384
Net Cash Provided by (Used in) Financing Activities [Abstract]
Principal payments on capital leases	(120)	0	0
Proceeds from issuance of common stock upon exercise of stock options	6,628	4,319	3,438
Tax payments related to shares withheld for vested restricted stock units	(8,283)	(6,594)	(876)
Tax effect of employee stock plans	1,357	87	0
Net cash provided by (used in) financing activities	(418)	(2,188)	2,562
Effect of exchange rate on cash and cash equivalents	(709)	(462)	57
NET INCREASE IN CASH AND CASH EQUIVALENTS	7,061	2,851	2,922
CASH AND CASH EQUIVALENTS—Beginning of period	28,649	25,798	22,876
CASH AND CASH EQUIVALENTS—End of period	$ 35,710	$ 28,649	$ 25,798

The Company and Basis of Presen

The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company and Basis of Presentation ZELTIQ Aesthetics, Inc. (the “Company”) was incorporated in the state of Delaware on March 22, 2005 . The Company was founded to develop and commercialize a non-invasive product for the selective reduction of fat. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes precisely controlled cooling to reduce the temperature of fat cells in the treated area, which leads to fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. The Company generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers. In August 2011 , the Company incorporated ZELTIQ Limited as a wholly-owned subsidiary in the United Kingdom to serve as its sales office for direct sales in Europe. In December 2014 , the Company incorporated ZELTIQ Ireland Limited and ZELTIQ Ireland International Limited as wholly-owned subsidiaries in Ireland for additional office support in Europe. In December 2015 , the Company also incorporated ZELTIQ Ireland International Holdings Unlimited Company. Out of period adjustments During the three months ended December 31, 2015, the Company recorded an out-of-period correcting adjustment of $0.3 million to increase cost of revenue to write-off certain inventory related to service parts. Of this adjustment, $0.2 million related to the three months ended September 30, 2015 and the remainder primarily in the other quarters of 2015. The Company does not believe that such amounts are material to any prior period consolidated financial statements, and the impact of correcting these errors in the three months ended December 31, 2015 is not material to the current consolidated financial statements. During the three months ended June 30, 2015, the Company recorded an out-of-period correcting adjustment of $0.2 million to increase cost of revenue to write-off of certain inventory held by vendors. Of this adjustment, $0.1 million , $23,000 and $42,000 related to the fiscal years ended December 31, 2012, 2013 and 2014, respectively. The Company does not believe that such amounts are material to any prior period consolidated financial statements, and the impact of correcting these errors in the year ended December 31, 2015 is not material to the current consolidated financial statements. During the three months ended December 31, 2014, the Company recorded an out-of-period correcting adjustment related to stock-based compensation that resulted in $0.7 million of revenue reduction. The adjustment to revenue resulted from an error in the application of generally accepted accounting principles related to payments to customers for services starting in the second quarter of 2013 through the third quarter of 2014. Of the total amount of this adjustment, $0.4 million related to the fiscal year ending December 31, 2013. The error caused the overstatement of revenue and sales and marketing expense in prior periods due to the misclassification of this stock-based compensation. This adjustment did not have any impact to the Company's consolidated net income (loss) as reported in the consolidated statements of operations in any current or prior interim or annual period. The Company does not believe that such amounts are material to current and previously reported consolidated financial statements. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP. Certain amounts in the prior year's consolidated financial statements have been reclassified to conform to the current period's presentation. These reclassifications had no impact on previously reported consolidated statements of cash flows or statements of operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. The primary estimates underlying the Company's financial statements include the value of revenue elements, accruals for discretionary customer programs and payments, product warranties, inventory valuation, allowance for doubtful accounts receivable, assumptions regarding variables used in calculating the fair value of the Company's equity awards, fair value of investments, useful lives of intangibles, income taxes and contingent liabilities. Actual results could differ from those estimates. Significant Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, competition from substitute products and larger companies, ability to protect proprietary technology from copy-cat or counterfeit versions the Company's products, strategic relationships and dependence on key individuals. If the Company fails to adhere to ongoing Food and Drug Administration, or FDA, Quality System Regulation, the FDA may withdraw its market clearance or take other action. The Company relies on sole-source suppliers to manufacture some of the components used in its product. The Company's manufacturers and suppliers may encounter supply interruptions or problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA's Quality System Regulation, equipment malfunction and environmental factors, any of which could delay or impede the Company's ability to meet demand. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, marketable securities and trade receivables. The Company's cash equivalents and marketable securities are held in safekeeping by large, credit worthy financial institutions. The Company invests its excess cash primarily in U.S. banks, government and agency bonds, money market funds and corporate obligations. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management's assessment of the collectability of specific customer accounts and the aging of the related invoices, and represents the Company's best estimate of probable credit losses in its existing trade accounts receivable. At December 31, 2015 and 2014 , the Company's allowance for doubtful accounts was $1.2 million and $0.3 million , respectively. The allowance for doubtful accounts consisted of the following activity for fiscal years ended December 31, 2015 , 2014 and 2013 (in thousands): Description Balance at Beginning of Year Charge to expense Write-offs, net of recoveries Balance at End of Year Year ended December 31, 2013 $ 330 $ 59 $ (389 ) $ — Year ended December 31, 2014 — 469 (145 ) 324 Year ended December 31, 2015 $ 324 $ 1,032 $ (173 ) $ 1,183 As of December 31, 2015 and 2014 , Ideal Image, which is a large aesthetic chain, along with its affiliated franchises, accounted for 10% and 24% of accounts receivable, respectively. Furthermore, Ideal Image and its affiliated franchises accounted for 10% of total revenue during the year ended December 31, 2015 . No individual customer accounted for greater than 10% of total revenue during the years ended December 31, 2014 and 2013 . Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Investments The Company invests its excess cash balances primarily in certificates of deposit, commercial paper, corporate bonds, and U.S. Government agency securities. Investments with original maturities greater than 90 days that mature less than one year from the consolidated balance sheet date are classified as short-term investments. The Company classifies all of its investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of accumulated other comprehensive income (loss) in stockholders' equity. Realized gains and losses from maturities of all such securities are reported in earnings and computed using the specific identification cost method. Realized gains or losses and charges for other-than-temporary declines in value, if any, on available-for-sale securities are reported in other income (expense), net as incurred. The Company periodically evaluates these investments for other-than-temporary impairment. Inventory Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or market. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory. Property and Equipment Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. The useful lives of the property and equipment are as follows: Lab equipment, tooling, and molds 5 years Computer equipment 3 years Computer software 3 years Furniture and fixtures 5 years Vehicles 5 years Leasehold improvements Shorter of lease term or estimated useful life Capitalized Software The Company capitalizes costs associated with customized internal-use software systems that have reached the application development stage and meet recoverability tests. Such capitalized costs mainly include external direct costs utilized in developing or obtaining the applications. Capitalization of such costs begins when the preliminary project stage is complete and ceases at the point in which the project is substantially complete and is ready for its intended purpose. The capitalized costs associated with internal-use software are depreciated on a straight-line basis over each asset's estimated useful life, which is generally three years. Restricted Cash At December 31, 2015 and 2014 , cash of $0.5 million and $0.6 million , respectively, was restricted from withdrawal and held by banks in the form of certificates of deposit. At December 31, 2015 and 2014 , the certificates of deposit were held as collateral for the facility lease agreement in Pleasanton, California, and for its United Kingdom banking facilities and credit card programs. Intangible Asset The intangible asset consists of an exclusive license agreement for commercializing patents and other technology. All milestone payments subsequent to the date of the FDA approval are capitalized as purchased technology when paid, and are subsequently amortized into cost of revenue using the straight-line method over the estimated remaining useful life of the technology, not to exceed the term of the agreement or the life of the patent. Impairment of Long-lived Assets The Company reviews property and equipment and the intangible asset for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the assets' fair value determined using the projected discounted future net cash flows arising from the asset. Thr ough December 31, 2015 , there have been no such impairments. Revenue Recognition The Company’s revenue is derived from the sales of the CoolSculpting system, consisting of a control unit and applicators, and, from time to time, related extended warranty arrangements, and from the sale of cycles in the form of consumable procedure packs, each of which includes consumable CoolGels, CoolLiners, and in the case of the Company's CoolSmooth procedure packs, disposable securement accessories, all of which are used by the Company's customer during treatments. The Company earns revenue from the sale of these products to its customers and to distributors. The Company recognizes revenue when persuasive evidence of an arrangement exists, transfer of title to the customer has occurred, the sales price is fixed or determinable, and collectability is probable. Revenue is deferred in the event that any of the revenue recognition criteria is not met. Each consumable procedure pack includes a disposable computer cartridge that the Company markets as the CoolCard. The CoolCard contains enabling software that permits the Company's customers to perform a fixed number of CoolSculpting procedures, or cycles. This software is not marketed separately from the CoolSculpting system or from the CoolCard. Rather, the functionality that the software provides is part of the overall CoolCard product. The CoolSculpting system is marketed as a non-invasive aesthetic device for the selective reduction of fat, not for its embedded software attributes included in the CoolCard that enable its use. The Company does not provide rights to upgrades and enhancements or post-contract customer support for the embedded software. In addition, the Company does not incur significant software development costs or capitalize its software development costs. Based on this assessment, the Company considers the embedded software in the CoolCard incidental to the CoolCard product as a whole and determined that revenue recognition should not be governed by the provisions of Topic 985 of the FASB Accounting Standards Codification, or ASC. Persuasive Evidence of an Arrangement. The Company uses contracts or customer purchase orders to determine the existence of an arrangement. Delivery . The Company's standard terms specify that title transfers upon shipment to the customer. The Company uses third party shipping documents to verify that title has transferred. Sales Price Fixed or Determinable. The Company assesses whether the sales price is fixed or determinable at the time of the transaction. Sales prices are documented in the executed sales contract or purchase order received prior to shipment. The Company’s standard terms do not allow for trial or evaluation periods, rights of return or refund, payments contingent upon the customer obtaining financing or other terms that could impact the customer’s obligation. Collectability. The Company assesses whether collection is reasonably assured based on a number of factors, including the customer’s past transaction history and credit worthiness. Multiple-Element Arrangements. Typically, all products sold to a customer are delivered at the same time. If a partial delivery occurs as authorized by the customer, the Company allocates revenue to the various products based on their vendor-specific objective evidence of fair value, or VSOE, if VSOE exists according to ASC 605-25 as the basis of determining the relative selling price of each element. If VSOE does not exist, the Company may use third party evidence of fair value, or TPE, to determine the relative selling price of each element. If neither VSOE nor TPE exists, the Company may use management’s best estimate of the sales price, or ESP, of each element to determine the relative selling price. The relative selling prices for control units, applicators, CoolCards and extended warranty are based on established price lists and separate, stand-alone sales of these elements. The Company establishes best estimates within a range of selling prices considering multiple factors including, but not limited to, factors such as size of transaction, pricing strategies and market conditions. The Company believes the use of the ESP allows revenue recognition in a manner consistent with the underlying economics of the transaction. The Company’s products do not require maintenance or support. Additionally, from time to time there may be undelivered elements in a multiple element arrangement, such elements generally being training or extended warranty. The Company defers revenue on undelivered elements of an arrangement and recognizes it once all revenue recognition criteria have been met. Customer Programs and Payments The Company regularly evaluates the adequacy of its estimates for product returns, cooperative marketing arrangements, customer incentive programs and pricing programs. Future market conditions and product transitions may require the Company to take action to change such programs. In addition, when the variables used to estimate these costs change, or if actual costs differ significantly from the estimates, the Company would be required to record incremental increased or reductions to sales, cost of goods sold or operating expenses. If, at any future time, the Company becomes unable to reasonably estimate these costs, recognition of revenue might be deferred until products are sold to users, which would adversely impact sales in the period of transition. Accruals for Customer Programs The Company records an accrued liability for cooperative marketing arrangements and customer incentive programs. The estimated cost of these programs is recorded as a reduction of revenue or as an operating expense, if the Company receives a separately identifiable benefit from the customer and can reasonably estimate the fair value of that benefit. Significant management judgment and estimates must be used to determine the cost of these programs in any accounting period. Cooperative Marketing Arrangements. The Company offers cooperative marketing programs to its North American customers, allowing the customers to receive partial reimbursement for qualifying advertising expenditures which promote the Company's product and brand. Customer participation, as well as reimbursement amounts, is predicated upon purchase levels of CoolCards. The objective of these arrangements is to encourage advertising and promotional events to increase sales of the Company's products. Accruals for these marketing arrangements are recorded at the later of time of sale, or time of commitment, based on the related program parameters, review of related advertising and historical experience. Customer Incentive Programs. The Company's customer incentive program consists of rebates for its distributors based on purchase levels. Estimated costs of customer rebates and similar incentives are recorded at the later of the time the incentive is offered, based on the specific terms and conditions of the program or the time the related revenue is recognized. Customer incentive programs include performance-based incentives and consumer rebates. The Company offers performance-based incentives to its distributor customers, direct partners and indirect partners based on pre-determined performance criteria. Accruals for performance-based incentives are recognized as a reduction of the sale price at the later of the time the incentive is offered, based on the specific terms and conditions of the program or the time the related revenue is recognized. Estimates of required accruals are determined based on negotiated terms, consideration of historical experience, anticipated volume of future purchases, and inventory levels in the channel. Certain incentive programs require management to estimate the number of customers who will actually redeem the incentive based on historical experience and the specific terms and conditions of particular programs. Accounting for Payments to Customers The Company occasionally enters into transactions where it provides consideration to its customers in the forms of cash payments or stock-based awards in exchange for certain goods and services. The Company accounts for such payments to customers in accordance with ASC 605-50, Revenue Recognition: Customer Payments and Incentives, which requires management to characterize the payment as a reduction of revenue if it is unable to demonstrate the receipt of a benefit that is identifiable and sufficiently separable from the revenue transaction and reasonably estimate the fair value of the benefit identified. Significant management judgment and estimates must be used to determine the fair value of the benefit received in any period. For stock awards, the Company believes that the fair value of the awards is more reliably measured than the fair value of the benefit received. The fair value of the stock awards is measured as of the date at which either the commitment for performance by the customer to earn the award is reached or the date the customer’s performance is complete. Until that point is reached, the award is revalued at each reporting period with the true-up to fair value recorded in current period earnings. Cost of Revenue Cost of revenue consists primarily of cost of finished and semi-finished products purchased from the Company's third-party suppliers, labor, material, and overhead involved in its internal manufacturing processes, technology amortization and royalty fees and cost of product warranty. In the event that a revenue transaction is deferred, the corresponding cost associated with the transaction will also be deferred. Shipping and Handling Shipping and handling costs charged to customers are recorded as revenue. Shipping costs are included in cost of revenue. Research and Development Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, and allocated facilities costs for employees and contractors engaged in research, clinical studies, regulatory affairs, and development. The Company expenses all research and development costs in the periods in which they are incurred. Advertising costs The cost of advertising and media is expensed as incurred. For the years ended December 31, 2015 , 2014 and 2013 , advertising costs totaled $17.4 million , $7.9 million and $8.9 million , respectively. Product Warranties The Company provides a standard limited warranty on its products of one year for both control units and applicators for its direct customers. For indirect customers in international markets, the Company provides a standard limited warranty on its products of approximately three years for control units and one year for applicators. The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based upon historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. The Company bases product warranty costs on related freight, material, technical support labor and overhead costs. The estimated product warranty costs are assessed by considering historical costs and applying the experienced failure rates to the outstanding warranty period for products sold. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, and average repair costs, including freight, material, technical support labor, and overhead costs, for products returned under warranty. The Company offers an extended warranty on both its CoolSculpting control units and CoolSculpting applicators. The Company recognizes the revenue from the sale of an extended warranty over the extended warranty coverage period. The Company's revenue recognized from the sale of extended warranties for the years ended December 31, 2015 , 2014 and 2013 were $3.5 million , $2.1 million and $1.0 million , respectively. Stock-Based Compensation The Company maintains incentive plans under which incentive and nonqualified stock options are granted primarily to employees and non-employee consultants. Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. The fair value of stock-based awards to employees is estimated using the Black-Scholes option pricing model. The Company estimates its forfeiture rate based on an analysis of its actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate assumption based on actual forfeitures, analysis of employee turnover, and other related factors. Stock-based compensation expense related to stock options granted to non-employees is recognized as the stock options are earned. The awards generally vest ratably over the time period the Company expects to receive services from the non-employee. The fair values attributable to these options are amortized over the service period and the unvested portion of these options is remeasured at each vesting date. Income Taxes The Company utilizes the asset and liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse and for operating losses and tax credit carryforwards. The Company estimates its income taxes and amounts ultimately payable or recoverable in multiple tax jurisdictions around the world. Estimates involve interpretations of regulations and are inherently complex. Resolution of income tax treatments in individual jurisdictions may not be known for many years after completion of any fiscal year. The Company is required to evaluate the realizability of its deferred tax assets on an ongoing basis to determine whether there is a need for a valuation allowance with respect to such deferred tax assets. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considers all available positive and negative evidence giving greater weight to its recent cumulative losses and its ability to carryback losses against prior taxable income and, commensurate with objective verifiability, the forecast of future taxable income including the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement. The Company reports a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company adjusts these reserves in light of changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the provision for income taxes in the period in which such determination is made. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate, as well as the related net interest. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax provision. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheet. The Company files annual income tax returns in multiple taxing jurisdictions around the world. A number of years may elapse before an uncertain tax position is audited and finally resolved. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its reserves for income taxes reflect the most likely outcome. The Company adjusts these reserves, as well as the related interest, in light of changing facts and circumstances. Settlement of any particular position could require the use of cash or loss of tax attributes. At December 31, 2015, based on the Company's evaluation of the positive and negative evidence described in Note 11-Income Taxes, the Company concluded that the positive evidence outweighed the negative evidence and that it was more likely than not that the Company will realize all of its U.S. federal and state deferred tax assets, except for deferred tax assets related to California R&D credits. Consequently, at December 31, 2015, the Company reduced its deferred tax asset valuation allowance to $2.5 million . At December 31, 2014, the Company had a full valuation allowance against its U.S. deferred tax assets, net of expected reversals of existing deferred tax liabilities. Net Income (Loss) Per Share Basic net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) per share of common stock is computed by giving effect to all potentially dilutive securities outstanding during the period, including options, restricted stock units and common stock issuable pursuant to the ESPP. Comprehensive Income (Loss) Accumulated other comprehensive income (loss) includes foreign currency translation adjustments and unrealized gains (losses) on available-for-sale securities net of tax, the impact of which has been excluded from earnings and reflected as components of stockholders' equity. Components of accumulated other comprehensive loss was as follows (in thousands): December 31, 2015 2014 Cumulative translation adjustments $ (1,615 ) $ (690 ) Unrealized loss on marketable securities, net of tax (21 ) (6 ) Accumulated other comprehensive loss $ (1,636 ) $ (696 ) Foreign currency translation Based on an evaluation of economic facts and circumstances together with the functional currency analysis prescribed in ASC 830, Foreign Currency Matters , on October 1, 2013, the Company changed the functional and reporting currency for its operations in the United Kingdom from the U.S. Dollar to the British Pound. Such change did not have a material impact on the consolidated financial statements of the Company. The functional and reporting currency is the Euro for the Company's operations in Ireland and the U.S. dollar for all of its other foreign operations. All assets and liabilities of the Company's operations in the United Kingdom and Ireland are translated to U.S. Dollars at current period end exchange rates, and revenue and expenses are translated to U.S. Dollars using average exchange rates in effect during the period. The gains and losses from the foreign currency translation of the foreign subsidiaries' financial statements are included as a separate component of stockholders' equity under "Accumulated other comprehensive income (loss)." Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in other income (expense), net. For the years ended December 31, 2015 , 2014 and 2013 , such amount totaled $(0.3) million , $(0.3) million and $24,000 , respectively. Recent Accounting Pronouncements On May 28, 2014 , the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. On August 12, 2015 , the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delays the effective date of ASU 2014-09 by one year. The objective of this update is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. This standard update contains principles that the Company will apply to determine the measurement of revenue and timing of when it is recognized. This guidance allows for two methods of adoption: (a) full retrospective adoption, meaning the guidance is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying this guidance is recognized as an adjustment to the fiscal 2018 opening accumulated deficit balance. The Company expects to adopt this guidance effective January 1, 2018 , and is currently evaluating the two adoption methods as well as the impact this new guidance will have on its consolidated financial statements and related disclosures. In August 2014 , the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern. This standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016 . The new guidance is not expected to have an impact on the Company's consolidated financial statements and related disclosures. In April 2015 , the FASB issued Accounting Standards Update No. 2015-05 regarding Subtopic 350-40, “Intangibles - Goodwill and Other - Internal-Use Software.” This standard provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, the customer should account for the software license element of the arrangement consistent with other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The amendments are effective for annual and interim periods beginning after December 15, 2015 . Early adoption is permitted. The amendments may be applied either prospectively to all arrangements entered into or materially modified after the effective date or retrospectively. The Company is currently evaluating the impact this new guidance will have on its consolidated financial statements and related disclosures. In June 2015 , the FASB issued Accounting Standards Update No. 2015-10, Technical Corrections and Improvements. The standard covers a wide range of Topics in the Codification. The amendments in this standard represent changes to clarify the Codification, correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost on most entities. The amendments are effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2015 . The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements and footnote disclosures. The Company is c

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company did not hold any Level 3 assets or liabilities at December 31, 2015 . The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company classifies its cash equivalents and investments within Level 1 and Level 2, as it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs. The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): As of December 31, 2015 Level 1 Level 2 Level 3 Fair Value Financial Assets Cash equivalents: Money market funds $ 1,342 $ — $ — $ 1,342 Short-term investments: U.S. Agency securities — 1,549 — 1,549 U.S. Treasury — 500 — 500 Corporate bonds — 7,763 — 7,763 Commercial paper — 500 — 500 Certificates of deposit 2,555 — — 2,555 Long-term investments: U.S. Agency securities — 497 — 497 Corporate bonds — 874 — 874 Certificates of deposit 2,119 — — 2,119 Total $ 6,016 $ 11,683 $ — $ 17,699 As of December 31, 2014 Level 1 Level 2 Level 3 Fair Value Financial Assets Cash equivalents: Money market funds $ 6,062 $ — $ — $ 6,062 Short-term investments: U.S. Agency securities — 5,240 — 5,240 U.S. Treasury — 1,004 — 1,004 Corporate bonds — 7,774 — 7,774 Commercial paper — 1,349 — 1,349 Certificates of deposit 919 — — 919 Long-term investments: U.S. Agency securities — 999 — 999 U.S. Treasury — 500 — 500 Corporate bonds — 750 — 750 Certificates of deposit 2,556 — — 2,556 Total $ 9,537 $ 17,616 $ — $ 27,153 During the years ended December 31, 2015 and 2014 , the Company did not have any transfers of financial assets measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3. The Company did not hold any Level 3 assets or liabilities as of December 31, 2015 and December 31, 2014 . The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate fair value due to their relatively short maturities.

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Investments The Company's short-term and long-term investments as of December 31, 2015 are as follows (in thousands): Short-term Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Agency securities $ 1,551 $ — $ (2 ) $ 1,549 U.S. Treasury 500 — — 500 Corporate bonds 7,776 — (13 ) 7,763 Commercial paper 500 — — 500 Certificates of deposit 2,555 — — 2,555 Total $ 12,882 $ — $ (15 ) $ 12,867 Long-term Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Agency securities $ 499 $ — $ (2 ) $ 497 U.S. Treasury — — — — Corporate bonds 878 — (4 ) 874 Certificates of deposit 2,119 — — 2,119 Total $ 3,496 $ — $ (6 ) $ 3,490 The Company's short-term and long-term investments as of December 31, 2014 are as follows (in thousands): Short-term Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Agency securities $ 5,240 $ 1 $ (1 ) $ 5,240 U.S. Treasury 1,003 1 — 1,004 Corporate bonds 7,778 2 (6 ) 7,774 Commercial paper 1,349 — — 1,349 Certificates of deposit 919 — — 919 Total $ 16,289 $ 4 $ (7 ) $ 16,286 Long-term Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Agency securities $ 1,000 $ — $ (1 ) $ 999 U.S. Treasury 500 — — 500 Corporate bonds 752 — (2 ) 750 Certificates of deposit 2,556 — — 2,556 Total $ 4,808 $ — $ (3 ) $ 4,805 For the years ended December 31, 2015 and 2014 , gains or losses realized on the sale of investments were insignificant. The contractual maturities of the Company's short-term and long-term investments as of December 31, 2015 are as follows (in thousands): December 31, 2015 Amortized Cost Fair Value Due in one year or less $ 12,882 $ 12,867 Due in one year to five years 3,496 3,490 $ 16,378 $ 16,357 When evaluating the investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below the amortized cost basis, review of current market liquidity, interest rate risk, the financial condition of the issuer, as well as credit rating downgrades. The Company believes that the unrealized losses are not other-than-temporary. The Company does not have a foreseeable need to liquidate the portfolio and anticipates recovering the full cost of the securities either as market conditions improve, or as the securities mature. Inventory The components of inventory consist of the following (in thousands): December 31, 2015 2014 Raw materials $ 9,117 $ 7,692 Finished goods 18,978 7,844 Total inventory $ 28,095 $ 15,536 Property and equipment, net Property and equipment, net comprised the following (in thousands): December 31, 2015 2014 Lab equipment, tooling and molds $ 3,228 $ 2,766 Computer software 2,019 1,337 Computer equipment (1) 2,757 1,366 Leasehold improvements (1) 1,670 1,070 Furniture and fixtures 950 494 Vehicles 35 35 Total property and equipment 10,659 7,068 Less: Accumulated depreciation and amortization (5,635 ) (4,111 ) Construction in progress 1,945 767 Property and equipment, net $ 6,969 $ 3,724 Depreciation and amortization expense related to property and equipment was $1.7 million , $1.1 million and $1.0 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. (1) During fiscal year 2015, the Company determined that the 2014 leasehold improvements category incorrectly contained computer equipment of $0.4 million . The table above has been revised to correctly reflect these assets within the computer equipment category in the 2014 comparable numbers. The Company concluded that this adjustment was not material to the previously issued consolidated financial statements. Accrued and Other Current Liabilities The following table shows the components of accrued liabilities (in thousands): December 31, 2015 2014 Accrued payroll and employee related expenses $ 14,887 $ 8,386 Accrued marketing expenses 5,554 2,959 Accrued royalty 5,453 3,612 Sales and other taxes payable 3,703 2,123 Advance payments from customers 1,585 1,908 Accrued legal expenses 1,465 592 Accrued warranty 527 569 Other 1,517 1,301 Total accrued and other current liabilities $ 34,691 $ 21,450 Deferred Revenue The following table shows the components of deferred revenue, including long-term deferred revenue (in thousands): December 31, 2015 2014 Deferred revenue $ 1,347 $ 573 Deferred extended warranty revenue 2,902 3,272 Deferred training revenue 3,115 1,381 Other deferred revenue 544 465 Total deferred revenue $ 7,908 $ 5,691 Deferred Extended Warranty Revenue The Company offers standard extended warranties which allows customers to receive service and support which extend beyond the contractual term of the product warranty. The Company recognizes these contracts over the life of the service period. Changes in the Company's deferred revenue, including long-term deferred revenue, related to extended warranties were as follows (in thousands): Year Ended December 31, 2015 2014 Balance at the beginning of the period $ 3,272 $ 1,443 Extended warranties issued 3,158 3,897 Amortization (3,528 ) (2,068 ) Balance at the end of the period $ 2,902 $ 3,272 Product Warranties The estimated product warranty accrual was as follows (in thousands): Year Ended December 31, 2015 2014 Balance at the beginning of the period $ 569 $ 676 Settlement of pre-existing warranties (658 ) (772 ) Provision 616 665 Balance at the end of the period $ 527 $ 569

License Agreement With Massachu

License Agreement With Massachusetts General Hospital	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
License Agreement with Massachusetts General Hospital	License Agreement with Massachusetts General Hospital In May 2005, the Company entered into an exclusive license agreement with the General Hospital Corporation, a not for profit Massachusetts corporation, which owns and operates the Massachusetts General Hospital, or MGH. This agreement was amended and restated in September 2011. Under this agreement, the Company obtained an exclusive license to develop and commercialize the patent and the core technology that underlies its CoolSculpting system. The Company conducted development from 2005 through 2009, and thereafter started commercialization of the products. The agreement will remain in full force and effect for the later of (i) the life of any patents that issue from the underlying patent applications, which are expected to expire in 2023 or (ii) one year after the last commercial sale for which a royalty is due to MGH, unless terminated in accordance with its terms and conditions. MGH may terminate the agreement upon the Company's insolvency, failure to maintain insurance, material breach of the agreement including failure to satisfy the Company's post-sales requirements, or failure to make required payments. The Company may terminate the agreement for any reason upon 90 days' advance written notice to MGH. The Company has complied with its contractual requirements to date. The Company is obligated to make various payments to MGH, including (i) a 7% royalty on net sales (as defined in the agreement) of CoolSculpting and (ii) milestone payments. During the year ended December 31, 2010, the Company paid MGH a $1.1 million milestone payment upon receipt of Food and Drug Administration, or FDA, clearance to market its CoolSculpting system for the selective reduction of fat. The remaining milestone payments including (i) $1 million due upon achieving cumulative net sales (as defined in the agreement) of $70 million and (ii) $6 million due upon the earlier to occur of achieving cumulative net sales (as defined in the agreement) of $200 million , or the completion of a qualifying initial public offering were made during the quarter ended December 31, 2011. As of December 31, 2011, the Company had completed all the milestones associated with the license agreement with MGH and had no milestone payments to MGH outstanding. All payments made to MGH prior to the FDA product clearance are expensed as incurred as research and development costs. All milestone payments payable by the Company pursuant to the terms of the agreement subsequent to the date of the FDA clearance were capitalized as purchased technology when paid, and are subsequently amortized into cost of revenue using the straight-line method over the estimated remaining useful life of the technology, not to exceed the term of the agreement or the life of the patent. Royalty payments are accrued as the Company recognizes revenue, and are included in cost of revenue. In September 2015, the Company entered into a new agreement with MGH to obtain an exclusive license to develop and commercialize certain patents and technology for the treatment of acne and certain related skin conditions. The Company is obligated to pay a 3% royalty on net sales, as defined in such agreement, of products incorporating such technology. The intangible asset, net comprised the following (in thousands): December 31, December 31, Purchased technology $ 8,050 $ 8,050 Less: Accumulated amortization (2,958 ) (2,270 ) Intangible asset, net $ 5,092 $ 5,780 The amortization expense of the intangible asset was $ 0.7 million for each of the years ended December 31, 2015 , 2014 and 2013 . The total estimated annual future amortization expense of this intangible asset as of December 31, 2015 , is as follows (in thousands): Year ending December 31, 2016 $ 650 2017 650 2018 650 2019 650 2020 650 Thereafter 1,842 Total $ 5,092

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Brazilian Distribution Agreement The Company entered into a distribution agreement with ADVANCE Medical, Inc. and its wholly owned subsidiaries, Immunotech and BIOGEN, or ADVANCE, dated March 18, 2011 , as the Company's exclusive distributor of CoolSculpting in Brazil and Mexico, as amended on August 29, 2011 , February 27, 2012 and September 4, 2012 . The distribution agreement was further amended on August 15, 2014, whereby ADVANCE is no longer a distributor in Mexico, effective November 13, 2014 . As the exclusive distributor in Brazil, ADVANCE is required to purchase a minimum quantity of the Company’s products each calendar quarter throughout the term of the distribution agreement which expires on December 31, 2018 . Venrock, a principal stockholder of the Company, owns an equity interest in ADVANCE Medical, Ltd., the parent company of ADVANCE. Dr. Bryan E. Roberts, who is a member of the Company's Board of Directors, is also a partner of Venrock Associates. ADVANCE purchases product with payment terms up to 180 days, and to date no amounts have been determined to be unrecoverable. The revenue recognized by the Company under this distribution agreement for the years ended December 31, 2015 , 2014 and 2013 , was $3.6 million , $1.9 million and $1.6 million , respectively. The accounts receivable balance under this distribution agreement as of December 31, 2015 and 2014 , was $1.7 million and $0.2 million , respectively. During fiscal year 2015, the Company determined that the 2014 and 2013 related party revenue disclosures were overstated by $0.2 million and $0.7 million , respectively, due to the incorrect inclusion of revenue from a non-related party customer. The amounts above have been revised to correct for these errors. The Company concluded that these adjustments were not material to the previously issued consolidated financial statements.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Lease Obligations The Company leases facilities under non-cancellable operating leases with various expiration dates. Specifically, the Company occupies a facility in Pleasanton, California, under a lease which extends through March 2019 , a manufacturing facility in Dublin, California, under a lease which extends through May 2017 , and a warehouse space in Livermore, California, under a lease which extends through May 2017 . The Company also occupies office and warehouse space near Gatwick, United Kingdom, under a lease which extends through December 2018 , as well as office space in London, United Kingdom, under a lease which extends through April 2016 , Taipei, Taiwan, under a lease which extends through August 2016 , Seoul, South Korea, under a lease which extends through August 2016 , Reston, Virginia, under a lease which extends through September 2020 , Galway, Ireland under two leases which extend through September 2016 and March 2016 , respectively. Rent expense for non-cancellable operating leases with scheduled rent increases is recognized on a straight-line basis over the lease term. Rent expense for the years ended December 31, 2015 , 2014 and 2013 , was $2.5 million , $1.5 million and $1.4 million , respectively. Future minimum lease payments under the non-cancellable operating leases as of December 31, 2015 , are as follows (in thousands): Year Ending December 31, Amount 2016 $ 2,344 2017 2,058 2018 1,912 2019 763 2020 234 Total future minimum lease payments $ 7,311 Capital Lease Obligations The Company has entered into certain capital lease obligations to purchase equipment for operations which include a bargain purchase option. The underlying assets and related depreciation are included in the appropriate property and equipment category and related accumulated depreciation account. Property and equipment includes the following amounts under leases that have been capitalized as of December 31, 2015 and 2014 were as follows (in thousands): Useful life (Years) December 31, December 31, Computer equipment 3 $ 382 $ 382 Total capital leased equipment 382 382 Less: Accumulated depreciation and amortization (149 ) (21 ) Capital leased equipment, net $ 233 $ 361 Total depreciation of assets acquired under capital leases was $0.1 million and $21,000 for the years ended December 31, 2015 and December 31, 2014 , respectively, which is included in total depreciation and amortization expense. There were no such arrangements during the years ended December 31, 2013 . Future minimum payments required under capital leases as of December 31, 2015 , are as follows (in thousands): Year Ending December 31, Amount 2016 $ 132 2017 141 Total future payments $ 273 Less: Amount representing interest $ 11 Present value of future minimum payments 262 Less: Current portion 124 Long term portion $ 138 Purchase Commitments The Company had non-cancellable purchase obligations to contract manufacturers and suppliers for $5.9 million at December 31, 2015 . Unrecognized Tax Benefits The Company's gross liability for unrecognized tax benefits totaled $0.3 million , including estimated interest and penalties, as of December 31, 2015 , and is classified in long-term income taxes payable. The Company is unable to make a reasonably reliable estimate of the timing of payments in individual years due to uncertainties in the timing of tax audits, if any, or their outcomes. Legal Matters From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. Additionally, the Company may be subject to insurance related claims resulting from matters associated with CoolSculpting treatments. The Company records a liability in its consolidated financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. Management reviews these estimates in each accounting period as additional information becomes known and adjusts the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements. If a loss is probable but the amount of loss cannot be reasonably estimated, the Company discloses the loss contingency and an estimate of possible loss or range of loss (unless such an estimate cannot be made). The Company does not recognize gain contingencies until they are realized. Legal costs incurred in connection with loss contingencies are expensed as incurred. Product Liability Contingencies The Company has historically been and continues to be predominantly self-insured for any product liability losses related to its products. The Company obtains third-party insurance to limit its exposure to these claims, but this insurance is subject to a cap on reimbursement. Product liability losses are, by their nature, uncertain and are based upon complex judgments and probabilities. The Company accrues for reported claims and estimates for incurred, but not reported claims, to the extent that such losses can be reasonably estimated. The Company determines its accruals for probable product liability losses based on various factors, including historical claims and settlement experience. The total amount of self-insured product liability claims settled in the year ended December 31, 2015 was $0.7 million . The total amount of self-insured product liability claims settled during the year ended December 31, 2014 was not material. The amount of reported and estimated incurred but not known self-insured product liability claims pending was $1.1 million as of December 31, 2015 , which is recorded as an accrual on the Company's consolidated balance sheet and expected to be paid within one year. Such estimated claims were insignificant as of December 31, 2014 . Indemnifications In the normal course of business, the Company enters into contracts that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims, and the Company believes that the estimated fair value of these indemnification obligations is minimal and has not accrued any amounts for these obligations. Severance and Separation Agreements Effective December 3, 2013 , the Company's Chief Scientific Officer and Senior Vice President of Clinical entered into a separation agreement with the Company. As a result of this separation agreement, the Company incurred $0.3 million in termination benefits and $0.7 million in costs related to the modification of the employee's stock-based compensation, which were recorded during the year ended December 31, 2013. As of December 31, 2014, all of the termination benefits incurred during December 31, 2013 had been paid. No similar costs were incurred during the year ended December 31, 2015 and 2014.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity Preferred Stock The Company's Certificate of Incorporation, as amended in October 2011, authorizes the Company to issue 50,000,000 shares of preferred stock with a par value of $0.01 per share. At December 31, 2015 and 2014 , the Company had no preferred stock issued or outstanding. Common Stock Each share of common stock has the right to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of December 31, 2015 .

Stock-Based Compensation Plans

Stock-Based Compensation Plans	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Plans	Stock-Based Compensation Plans Equity Incentive Programs In 2005, the Company established its 2005 Stock Option Plan (the “2005 Plan”), covering employees, directors and consultants of the Company. Under the terms of the 2005 Plan, incentive and nonqualified stock option and stock purchase rights could be granted. In September 2011, upon the adoption of the Company's 2011 Equity Incentive Plan (the "2011 Plan") the Company ceased granting options under the 2005 Plan. The 2011 Plan serves as the successor equity incentive plan to the Company's 2005 Plan and started with 89,234 shares of common stock available for issuance plus any shares of common stock issued pursuant to the 2005 Plan or subject to awards granted under the 2005 Plan that are forfeited, repurchased, returned or otherwise become available for issuance in accordance with the terms of the 2005 Plan. In addition, this plan reserve automatically increases on January 1 and each subsequent anniversary through January 1, 2021, by an amount equal to the smaller of five percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or an amount determined by the Company's Board of Directors. The 2011 Plan provides for granting awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units, cash-based awards and other stock-based awards. Options granted under the 2011 Plan may be either ISOs or NSOs. ISOs may be granted only to the Company's employees. Any person who is not an employee of the Company on the effective date of the grant of an option may be granted only a NSO. Options under the 2011 Plan may be granted for periods of up to ten years and generally vest over a period of four years . The exercise price of an ISO and NSO shall not be less than 100% of the fair value of the shares on the date of grant. The exercise price of an option granted to a 10% stockholder shall not be less than 110% of the fair value of the underlying stock on the date of grant. In April 2012, the Company's Board of Directors approved the 2012 Stock Plan ("2012 Plan") that became effective upon approval by the stockholders of the Company on June 15, 2012. The purpose of the 2012 Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The 2012 Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units, cash-based awards, other stock-based awards, and deferred compensation awards. The 2012 Plan started with 1,500,000 shares of common stock available for issuance and there are no provisions in the 2012 Plan to increase the shares available for issuance. Options granted under the 2012 Plan may be either ISOs or NSOs. ISOs may be granted only to the Company's employees. Any person who is not an employee of the Company on the effective date of the grant of an option may be granted only a NSO. Options under the 2012 Plan may be granted for periods of up to ten years and generally vest over a period of four years . The exercise price of an ISO and NSO shall not be less than 100% of the fair value of the shares on the date of grant. The exercise price of an option granted to a 10% stockholder shall not be less than 110% of the fair value of the underlying stock on the date of grant. Share-Based Awards Available for Grant A summary of share-based awards available for grant is as follows: Years Ended December 31, 2015 December 31, 2014 December 31, 2013 Balance at beginning of fiscal year 2,685,209 1,086,737 1,103,836 Additional shares reserved 1,000,000 1,851,794 1,200,000 Options granted (45,622 ) (255,000 ) (568,987 ) Restricted stock units granted (593,003 ) (508,729 ) (1,205,200 ) Options canceled 37,520 41,681 307,738 Restricted stock units canceled 174,094 157,358 163,689 Restricted stock unit withheld for tax 259,107 311,368 85,661 Balance at end of fiscal year 3,517,305 2,685,209 1,086,737 Stock Option Awards A summary of the stock option activity is as follows: Options Outstanding Number of Weighted- Weighted-Average Remaining Contractual Life (in Years) Aggregate Intrinsic Value (in thousands) Balance, December 31, 2012 4,128,334 4 $ 4.96 Options granted 568,987 6.60 Options exercised (791,198 ) 3.34 Options canceled (307,738 ) 7.36 Balance, December 31, 2013 3,598,385 $ 5.36 Options granted 255,000 18.42 Options exercised (569,283 ) 4.89 Options canceled (41,681 ) 5.50 Balance, December 31, 2014 3,242,421 $ 6.47 Options granted 45,622 34.65 Options exercised (608,931 ) 6.79 Options canceled (37,520 ) 8.55 Balance, December 31, 2015 2,641,592 $ 6.86 6.81 $ 57,532 Vested and expected to vest, December 31, 2015 2,620,217 $ 6.80 6.81 $ 57,187 Vested and Exercisable, December 31, 2015 2,127,228 $ 6.22 6.72 $ 47,457 The following table summarizes information about stock options outstanding as of December 31, 2015 : Options Outstanding Exercise Price Stock Options Outstanding Weighted-Average Remaining Contractual Life (in Years) Options Exercisable $0.55-4.60 278,755 6.6 185,111 4.62-4.62 90,000 6.9 55,625 5.04-5.04 1,431,092 6.6 1,252,213 5.06-6.34 295,572 6.9 242,576 6.38-10.20 287,135 6.5 240,224 11.30-17.44 56,229 7.4 32,267 17.48-17.48 90,000 8.4 90,000 20.88-20.88 47,187 8.1 20,105 21.00-21.00 20,000 8.2 9,167 $34.65-34.65 45,622 9.1 — 2,641,592 2,127,288 Restricted Stock Activity Activity related to restricted stock units and awards is set forth below: Number of Units and Awards Weighted- Balance, December 31, 2012 1,157,450 $ 5.38 Restricted stock units granted 1,205,200 5.57 Restricted stock units released (292,265 ) 5.35 Restricted stock units canceled (163,689 ) 4.31 Balance, December 31, 2013 1,906,696 $ 5.60 Restricted stock units granted 508,729 19.99 Restricted stock units released (724,986 ) 6.03 Restricted stock units canceled (157,358 ) 6.50 Balance, December 31, 2014 1,533,081 $ 10.08 Restricted stock units granted 593,003 31.96 Restricted stock units released (639,339 ) 10.76 Restricted stock units canceled (174,094 ) 14.16 Balance, December 31, 2015 1,312,651 $ 19.09 During the years ended December 31, 2015 , 2014 and 2013 , the Company withheld 259,107 , 311,368 and 85,661 shares, respectively, based upon the Company's closing stock price on the vesting date to settle the employee's minimum statutory obligation for the applicable income and other employment taxes. 2011 Employee Stock Purchase Plan In September 2011, the Company's Board of Directors approved the 2011 Employee Stock Purchase Plan (“2011 ESPP”) that became effective upon the completion of the IPO. The 2011 ESPP is designed to enable eligible employees to purchase shares of the Company's common stock at a discount. Each offering period consists of one six-month purchase period. The purchase price for shares of common stock under the 2011 ESPP is 85% of the of lesser of the fair market value of the Company's common stock on the first day of the applicable offering period or the purchase date. There were 470,018 shares of the Company's common stock initially reserved for future purchase under its 2011 ESPP. On the first day of each year, beginning January 1, 2012 and through and including January 1, 2021, the maximum aggregate number of shares of common stock that may be issued under the 2011 ESPP will be increased by a number of shares equal to the smallest of a) one percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or b) an amount determined by the Company's Board of Directors. During 2014, the number of shares of the Company's common stock reserved for future purchase under the 2011 ESPP was increased by 370,358 shares. During 2015, there were no additional shares of the Company's common stock reserved for future purchase under the 2011 ESPP. The employee stock purchase plan offering periods will commence on or about the first trading days of December and June of each year and end on or about the last trading days of the next May and November, respectively. During the year ended December 31, 2015 , employees purchased 108,552 shares under the 2011 ESPP at a weighted average exercise price of $22.96 . As of December 31, 2015 , there were 456,835 shares of the Company's common stock available for future purchase under its 2011 ESPP. Stock-Based Compensation Expense Stock-based compensation related to all of the Company's stock-based awards and employee stock purchases was recorded as an expense or a reduction to revenue and allocated as follows (in thousands): Year Ended December 31, 2015 2014 2013 Revenue $ 205 $ 833 $ — Cost of revenue 744 443 248 Research and development 1,619 1,073 1,645 Sales and marketing 5,129 2,917 1,783 General and administrative 5,522 4,117 2,984 Total stock-based compensation $ 13,219 $ 9,383 $ 6,660 Stock-based compensation expense includes charges related to performance based stock options and restricted stock units granted to certain executives. Stock-based compensation expense related to performance based stock options and restricted stock units was $2.5 million , $1.6 million and $1.0 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Stock-based compensation expense for the year ended December 31, 2013 includes $0.7 million in modification charges incurred in connection with the severance packages to the Company's former executives. There were no such charges for the years ended December 31, 2015 and 2014 . Stock-based compensation for the year ended December 31, 2015 and December 31, 2014 includes $0.2 million and $0.8 million , respectively, recorded as a reduction to revenue related to payments to customers for services. Of the total amount recorded as a reduction to revenue, $0.4 million is related to an out-of-period adjustment related to the fiscal year ended December 31, 2014 . As of December 31, 2015 , the total unrecognized compensation cost related to outstanding stock options, awards and employee stock purchases was $19.4 million , which is expected to be recognized over a weighted-average remaining period of 2.6 years . Stock-Based Compensation Associated with Awards to Employees The Company uses the Black-Scholes option pricing model to determine the fair value of stock options. The valuation model for stock compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term (weighted-average period of time that the options granted are expected to be outstanding); volatility of the Company's common stock, an assumed-risk-free interest rate and the estimated forfeitures of unvested stock options. The fair value of employee stock options was estimated using the following weighted-average assumptions: Year Ended December 31, 2015 2014 2013 Expected term (in years) 4.8 4.4 4.8 Expected volatility 63 % 43 % 51 % Risk-free interest rate 1.29 % 1.25 % 1.02 % Expected dividend yield 0 % 0 % 0 % Expected Term . Subsequent to the Company's initial public offering of its common stock, or IPO in 2011, and through 2014, the expected term used was based on expected term of a group of similar entities, referred to as its “peer group.” In evaluating similarity, the Company considered factors such as industry, stage of life cycle and size. In 2015, the Company modified its approach by including its own historical data along with the expected term of the identified peer group companies. The Company will continue to apply this methodology until a sufficient amount of historical information regarding its own expected term becomes available. Volatility . Subsequent to the IPO and through 2014, the Company continued to estimate its volatility based on the volatility of a group of similar entities, referred to as its "peer group". In evaluating similarity, the Company considered factors such as industry, stage of life cycle and size. In 2015, the Company modified its approach by including its own common stock trading history along with the volatility of the identified peer group companies. The expected stock price volatility is estimated using a combination of historical and peer group volatility to derive the expected volatility assumption. The Company believes the blended volatility is more representative of future stock price trends over the expected life of the options rather than just using historical or peer group volatility. The Company will continue to apply this methodology until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Risk-Free Interest Rate . The risk-free interest rate is based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. Dividend Yield . The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend yield of zero in the valuation model. Forfeitures. The Company is required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised. During the years ended December 31, 2015 , 2014 and 2013 , the Company granted 45,622 , 255,000 and 543,987 stock options, respectively, to employees with a weighted-average grant date fair value of $18.19 , $6.77 and $6.75 per share, respectively. The aggregate intrinsic value of options exercised was $2.8 million , $3.2 million and $6.8 million for the years ended December 31, 2015 , 2014 , and 2013 , respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company's common stock at the date of exercise. The total fair value of shares vested was $2.7 million , $4.3 million and $4.9 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. During the years ended December 31, 2015 , 2014 and 2013 , the Company granted 593,003 , 508,729 and 1,180,200 restricted stock units and restricted awards, respectively, to employees. The weighted-average grant date fair value as of the respective grant date of restricted stock units and restricted stock awards was $32.05 , $19.99 and $5.62 for the years ended December 31, 2015 , 2014 and 2013 , respectively. The fair value as of the respective vesting dates of restricted stock units and restricted stock awards was $6.4 million , $4.3 million and $1.4 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. There was no capitalized stock-based compensation cost during the years ended December 31, 2015 , 2014 and 2013 . The Company recognized stock-based compensation tax benefits of $1.3 million and $0.1 million during the years ended December 31, 2015 and December 31, 2014 , respectively. There was no recognized stock-based compensation tax benefits during the year ended December 31, 2013 . Stock-Based Compensation for Non-employees Stock-based compensation expense related to stock-based awards to non-employees is recognized as the stock-based awards are earned, generally through the provision of services. The Company believes that the fair value of the stock-based awards is more reliably measurable than the fair value of the services received. The fair value of the granted stock-based awards is calculated at each reporting date using the Black-Scholes option pricing model. During each of the years ended December 31, 2015 , 2014 and 2013 , the Company granted stock-based awards to non-employees which vest over 0.5 to 2.0 years . Stock-based compensation expense related to non-employee grants was $0.4 million , $0.6 million and $0.5 million for the years ended December 31, 2015 , 2014 and 2013 , respectively, of which $0.2 million and $0.8 million for an arrangement with a non-employee customer has been recorded as a reduction of revenue in the statement of operations during the years ended December 31, 2015 and December 31, 2014 , respectively. Included in the 2014 amount is $0.4 million of expense related to the year ended December 31, 2013 . Performance-Based Restricted Stock Units (PRSUs) From time to time, the Company will issue performance-based stock options and restricted stock units to senior executives. During the years ended December 31, 2015, 2014 and 2013, the Company granted 64,938 , 40,000 and 40,000 performance-based restricted stock units, respectively, to certain senior executives, which are accounted for as equity awards. The number of units that ultimately vest depends on achieving certain performance criteria and can range from 0% to 100% of the number of units granted. The performance criteria are specific to the roles of each of the executives and are set by the Compensation Committee of the Board of Directors. The performance-based restricted stock units have no dividend or voting rights during the performance period. Each of the performance-based restricted stock units represents the contingent right to receive one share of the Company's common stock if the vesting conditions are satisfied. Compensation expense related to these grants is based on the grant date fair value of the award. Total stock-based compensation related to performance-based restricted awards was $2.5 million , $0.8 million and $0.2 million in the years ended December 31, 2015, 2014 and 2013, respectively. As of December 31, 2015 , 34,938 PRSUs were outstanding.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans In 2005, the Company adopted a retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all employees in the United States who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the plan may be made at the discretion of the Board of Directors. Matching 401(k) contributions expensed were $1.8 million , $1.5 million and $1.1 million for the years ended December 31, 2015 , 2014 and 2013 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The domestic and foreign components of income (loss) before income taxes were as follows (in thousands): Year Ended December 31, 2015 2014 2013 Domestic $ 14,065 $ 1,443 $ (19,535 ) Foreign (10,733 ) 319 370 Income (loss) before income taxes $ 3,332 $ 1,762 $ (19,165 ) Provision for (benefit from) income taxes consisted of the following (in thousands): Year Ended December 31, 2015 2014 2013 Current provision: Federal $ 654 $ — $ — State 1,098 156 60 Foreign 183 94 61 Total current 1,935 250 121 Deferred provision (benefit): Federal (34,835 ) — — State (5,576 ) — — Foreign 6 (19 ) 19 Total deferred (40,405 ) (19 ) 19 Total provision for (benefit from) income taxes $ (38,470 ) $ 231 $ 140 The following is a reconciliation of the statutory federal income tax rate to the Company's effective tax: Year Ended December 31, 2015 2014 2013 Tax at federal statutory rate 35 % 35 % 35 % State income taxes, net of federal benefit 5 6 2 Non-deductible permanent difference 16 22 (1 ) Non-deductible executive compensation 51 150 — Change in valuation allowance (1,394 ) (157 ) (34 ) Research and development credits (36 ) (47 ) (2 ) Stock-based compensation 11 6 (1 ) Impact of foreign operations 153 (2 ) — Other tax adjustment 4 — — Effective tax rate (1,155 )% 13 % (1 )% The impact of foreign operations primarily relates to the differential between the United States federal statutory rate and lower foreign statutory rates, including a charge for a license payment made in one of our foreign subsidiaries which is incurred in a zero tax rate jurisdiction, due to the Company's tax planning action described below. Tax effects of temporary differences that give rise to significant portions of the deferred tax assets are presented below (in thousands): December 31, 2015 2014 Net operating loss carryforwards $ 19,829 $ 31,237 Income tax credits 5,867 4,838 Other Tax Credit 851 — Depreciation and amortization 4,855 5,615 Accruals and reserves 7,606 4,316 Stock-based compensation 3,950 2,790 Total deferred tax assets 42,958 48,796 Valuation allowance (2,483 ) (48,730 ) Net deferred tax assets $ 40,475 $ 66 As of December 31, 2015 , the Company had federal and state net operating loss carryforwards of $104.3 million and $96.3 million , respectively. The federal net operating losses begin expiring in 2025 and state net operating losses begin expiring in 2017 . As of December 31, 2015 , the Company had credit carryforwards of approximately $4.2 million and $4.8 million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal research and development credit carryforwards expire beginning 2025 , and state credits can be carried forward indefinitely. The federal and state net operating losses include $57.2 million and $22.9 million of excess stock based compensation that will result in increases to additional paid in capital, when realized. The valuation allowance for deferred tax assets consisted of the following activity for the fiscal years ended December 31, 2015, 2014 and 2013 (in thousands): Description Balance at Beginning of Year Additions Deductions Balance at End of Year Year ended December 31, 2013 $ 44,926 $ 6,077 $ — $ 51,003 Year ended December 31, 2014 51,003 1,011 (3,284 ) 48,730 Year ended December 31, 2015 $ 48,730 $ 673 $ (46,920 ) (1) $ 2,483 (1) Of this deduction, $40.4 million relates to the release in the valuation allowance, which was recorded as a deferred tax benefit during the year. Utilization of net operating losses and tax credit carryforwards may be limited by ownership change rules, as defined in Section 382 of the Internal Revenue Code. Similar rules may apply under state tax laws. The Company has assessed the application of Internal Revenue Code Section 382, during the fourth quarter of 2015 , and concluded no limitation currently applies, and the Company will continue to monitor activities in the future. In the event the Company experiences any subsequent changes in ownership, the amount of net operating losses and research and development credit carryovers available in any taxable year could be limited and may expire unutilized. During the year ended December 31, 2015 , the amount of gross unrecognized tax benefits increased by $1.4 million . The total amount of unrecognized tax benefits was $2.9 million as of December 31, 2015 . The Company recognizes interest and penalties related to uncertain tax positions as part of the income tax provision. To date, such interest and penalties have not been material. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Balance as of January 1, 2013 $ 902 Gross increase on tax positions related to the prior year 1,434 Gross increase on tax positions related to the current year 589 Balance as of December 31, 2013 2,925 Gross decrease on tax positions related to the prior year (1,746 ) Gross increase (decrease) on tax positions related to the current year 274 Balance as of December 31, 2014 1,453 Gross increase on tax positions related to the prior year 99 Gross increase on tax positions related to the current year 1,341 Balance as of December 31, 2015 $ 2,893 While it is often difficult to predict the final outcome of any particular uncertain tax position, management does not believe that it is reasonably possible that the estimates of unrecognized tax benefits will significantly change during the next twelve months. Each quarter the Company assesses the recoverability of its deferred tax assets under ASC 740, Income Taxes . The Company is required to establish a valuation allowance for any portion of the assets that the Company concludes is not more likely than not realizable. The Company's assessment considers, among other things, the three year cumulative net income, positive pretax net income and taxable income, forecasts of its future taxable income, carryforward periods, and its utilization experience with operating loss and tax credit carryforwards and tax planning actions. Management believes that, based on a number of factors, which include the Company's historical operating performance and cumulative U.S. taxable income during the three most recent years, the Company's tax planning action of migrating and licensing certain intellectual property to its foreign subsidiaries as well as its forecasted future taxable income, it is more-likely-than-not that it will realize a benefit from its Federal and certain State deferred tax assets within allowable net loss carryforward periods. As such, in fourth quarter of 2015, the Company released a valuation allowance of $40.4 million against its Federal and certain State deferred tax assets, with a corresponding deferred tax benefit during the quarter. Due to strong results during recent years and increased confidence that the Company will continue to generate taxable income into the foreseeable future, the Company's assessment regarding the potential to realize its deferred tax assets changed. With respect to California deferred tax assets, the Company believes that, except for California R&D credits, all other deferred tax assets would be realized in the future. Although the Company anticipates generating taxable income in California in future years, expected continued generation of California R&D credits along with existing net operating loss carryforwards of $73 million will be sufficient to offset California taxable income in the foreseeable future. As such, the Company's ability to utilize its current California R&D credit carryforwards is not more likely than not, and the Company continues to apply a valuation allowance against these deferred tax assets. For other states' deferred tax assets, the Company believes it is more likely than not that those deferred tax assets will be realized in the future and as a result does not apply a valuation allowance against those deferred tax assets. As of December 31, 2015, U.S. income taxes and foreign withholding taxes associated with the repatriation of undistributed earnings of foreign subsidiaries were not provided for on a cumulative total of $0.6 million . The Company intends to reinvest these earnings indefinitely in our foreign subsidiaries. If these earnings were distributed in the form of dividends or otherwise, or if the shares of the relevant foreign subsidiaries were sold or otherwise transferred, the Company would be subject to additional U.S. income taxes and foreign withholding taxes, net of related foreign tax credits. Determination of the amount of any unrecognized deferred income tax liability related to these earnings is not practicable because of the complexities of the hypothetical calculation. The Company files income tax returns in the U.S. federal and state jurisdictions, in the United Kingdom and Ireland and all returns since inception remain open to examination. On December 18, 2015, the President signed into law the Protecting Americans from Tax Hikes Act of 2015, which retroactively extends several expired tax provisions. Among the extended provisions is the Section 41 research credit for qualified research expenditures incurred through the end of 2015 . The benefit of the reinstated credit impacted the consolidated statement of operations in the period of enactment, which was the fourth quarter of 2015 due to the reversal of the valuation allowance on federal research and development credit carryforwards.

Net Income (Loss) per Share of

Net Income (Loss) per Share of Common Stock	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Net Income (Loss) per Share of Common Stock	Net Income (Loss) per Share of Common Stock Basic net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) per share of common stock is computed by giving effect to all potentially dilutive securities outstanding during the period, including stock options, restricted stock units and common stock issuable pursuant to the ESPP. A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net income (loss) per share is as follows: Year Ended December 31, 2015 2014 2013 Numerator Net income (loss) (in thousands) $ 41,802 $ 1,531 $ (19,305 ) Denominator Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic 38,754,643 37,563,590 36,209,051 Dilutive effect of incremental shares and share equivalents 2,041,003 3,433,382 — Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted 40,795,646 40,996,972 36,209,051 Net income (loss) per share: Net income (loss) per share, basic $ 1.08 $ 0.04 $ (0.53 ) Net income (loss) per share, diluted $ 1.02 $ 0.04 $ (0.53 ) Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the treasury stock method to calculate the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential dilutive common shares include unvested restricted stock awards and units and incremental common shares issuable upon the exercise of stock options, less shares from assumed proceeds. The assumed proceeds calculation includes actual proceeds to be received from the employee upon exercise, the average unrecognized stock compensation cost during the period and any tax benefits that will be credited upon exercise to additional paid-in capital. The following outstanding potentially dilutive securities were excluded from the computation of diluted net income (loss) per share of common stock for the periods presented, because including them would have been anti-dilutive: Year Ended December 31, 2015 2014 2013 Options to purchase common stock 39,497 220,712 3,598,385 Restricted stock units 26,290 12,723 1,906,696 Common stock issuable pursuant to the ESPP — — 86,026 Total 65,787 233,435 5,591,107

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	Supplemental Cash Flow Information The supplemental cash flow information consists of the following (in thousands): Year Ended December 31, 2015 2014 2013 Cash paid for interest $ 13 $ — $ — Cash paid for income taxes $ 38 $ 285 $ 188 Non-cash investing and financing activities: Assets acquired under capital leases $ — $ (382 ) $ — Accounts payable and accrued liabilities related to property, plant and equipment purchases $ 843 $ 106 $ 14

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has a single reportable segment structure. All of the Company’s principal operations and decision-making functions are located in the United States. The Company’s revenue by geographic region, based on the location to where the product was shipped, is summarized as follows (in thousands): Year Ended December 31, 2015 2014 2013 North America $ 193,376 $ 134,434 $ 89,150 International 62,040 40,044 22,476 Total $ 255,416 $ 174,478 $ 111,626 North America includes the United States and related territories as well as Canada. International is the rest of the world. Revenue for the United States was $180.5 million , $125.0 million and $83.7 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. The following table sets forth revenue by product expressed as dollar amounts (in thousands): Year Ended December 31, 2015 2014 2013 System revenue $ 130,698 $ 93,015 $ 61,359 Consumable revenue 124,718 81,463 50,267 Total $ 255,416 $ 174,478 $ 111,626 Substantially all of the Company’s long-lived assets are located in the United States of America.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On February 25, 2016, Patrick F. Williams, Senior Vice President and Chief Financial Officer and the Company mutually agreed that Mr. Williams would cease to be an officer and employee of the Company effective April 18, 2016.

Supplementary Financial Data (u

Supplementary Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Supplementary Financial Data (unaudited)	Supplementary Financial Data (unaudited) The following table presents selected unaudited consolidated financial data for each of the eight quarters in the two-year period ended December 31, 2015 . The selected quarterly financial data should be read in conjunction with the Company's consolidated financial statements and the related notes and "Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations." This information has been derived from the Company's unaudited consolidated financial statements that, in management's opinion, reflect all recurring adjustments necessary to fairly state this information when read in conjunction with the Company's consolidated financial statements and the related notes appearing in the section entitled "Consolidated Financial Statements," Net income (loss) per share-basic and diluted, for the four quarters of each fiscal year may not sum to the total for the fiscal year because of the different number of shares outstanding during each period. The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period. (In thousands, except share and per share data) Quarter First Second Third Fourth (1) Year Ended December 31, 2015 Total revenue $ 51,558 $ 64,431 $ 61,202 $ 78,225 Gross profit $ 37,180 $ 46,315 $ 45,161 $ 52,385 Net income (loss) $ (2,129 ) $ 1,178 $ 2,147 $ 40,606 Net income (loss) per share, basic $ (0.06 ) $ 0.03 $ 0.06 $ 1.04 Shares used in calculation-basic 38,383,022 38,649,873 38,881,183 39,093,825 Net income (loss) per share, diluted $ (0.06 ) $ 0.03 $ 0.05 $ 0.99 Shares used in calculation-diluted 38,383,022 41,641,660 40,860,593 40,966,744 Quarter First Second Third Fourth Year Ended December 31, 2014 Total revenue $ 30,975 $ 47,061 $ 45,670 $ 50,772 Gross profit $ 21,959 $ 33,401 $ 33,115 $ 35,939 Net income (loss) $ (7,337 ) $ 2,769 $ 4,782 $ 1,317 Net income (loss) per share, basic $ (0.20 ) $ 0.07 $ 0.13 $ 0.03 Shares used in calculation-basic 37,215,697 37,440,537 37,630,222 37,958,395 Net income (loss) per share, diluted $ (0.20 ) $ 0.07 $ 0.12 $ 0.03 Shares used in calculation-diluted 37,215,697 40,597,275 40,926,034 41,434,178 (1) In the fourth quarter of fiscal 2015, the Company released $40.4 million of its deferred tax asset valuation allowance. See Note 11 to the Consolidated Financial Statements.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. The primary estimates underlying the Company's financial statements include the value of revenue elements, accruals for discretionary customer programs and payments, product warranties, inventory valuation, allowance for doubtful accounts receivable, assumptions regarding variables used in calculating the fair value of the Company's equity awards, fair value of investments, useful lives of intangibles, income taxes and contingent liabilities. Actual results could differ from those estimates.
Significant Risks and Uncertainties	Significant Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company's products, competition from substitute products and larger companies, ability to protect proprietary technology from copy-cat or counterfeit versions the Company's products, strategic relationships and dependence on key individuals. If the Company fails to adhere to ongoing Food and Drug Administration, or FDA, Quality System Regulation, the FDA may withdraw its market clearance or take other action. The Company relies on sole-source suppliers to manufacture some of the components used in its product. The Company's manufacturers and suppliers may encounter supply interruptions or problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA's Quality System Regulation, equipment malfunction and environmental factors, any of which could delay or impede the Company's ability to meet demand.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, marketable securities and trade receivables. The Company's cash equivalents and marketable securities are held in safekeeping by large, credit worthy financial institutions. The Company invests its excess cash primarily in U.S. banks, government and agency bonds, money market funds and corporate obligations. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management's assessment of the collectability of specific customer accounts and the aging of the related invoices, and represents the Company's best estimate of probable credit losses in its existing trade accounts receivable.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Investments	Investments The Company invests its excess cash balances primarily in certificates of deposit, commercial paper, corporate bonds, and U.S. Government agency securities. Investments with original maturities greater than 90 days that mature less than one year from the consolidated balance sheet date are classified as short-term investments. The Company classifies all of its investments as available-for-sale and records such assets at estimated fair value in the consolidated balance sheets, with unrealized gains and losses, if any, reported as a component of accumulated other comprehensive income (loss) in stockholders' equity. Realized gains and losses from maturities of all such securities are reported in earnings and computed using the specific identification cost method. Realized gains or losses and charges for other-than-temporary declines in value, if any, on available-for-sale securities are reported in other income (expense), net as incurred. The Company periodically evaluates these investments for other-than-temporary impairment.
Inventory	Inventory Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or market. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred. Assets not yet placed in use are not depreciated. The useful lives of the property and equipment are as follows: Lab equipment, tooling, and molds 5 years Computer equipment 3 years Computer software 3 years Furniture and fixtures 5 years Vehicles 5 years Leasehold improvements Shorter of lease term or estimated useful life
Capitalized Software	Capitalized Software The Company capitalizes costs associated with customized internal-use software systems that have reached the application development stage and meet recoverability tests. Such capitalized costs mainly include external direct costs utilized in developing or obtaining the applications. Capitalization of such costs begins when the preliminary project stage is complete and ceases at the point in which the project is substantially complete and is ready for its intended purpose. The capitalized costs associated with internal-use software are depreciated on a straight-line basis over each asset's estimated useful life, which is generally three years.
Intangible Asset	Intangible Asset The intangible asset consists of an exclusive license agreement for commercializing patents and other technology. All milestone payments subsequent to the date of the FDA approval are capitalized as purchased technology when paid, and are subsequently amortized into cost of revenue using the straight-line method over the estimated remaining useful life of the technology, not to exceed the term of the agreement or the life of the patent.
Impairment of Long-Lived Assets	Impairment of Long-lived Assets The Company reviews property and equipment and the intangible asset for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the assets' fair value determined using the projected discounted future net cash flows arising from the asset.
Revenue Recognition	Revenue Recognition The Company’s revenue is derived from the sales of the CoolSculpting system, consisting of a control unit and applicators, and, from time to time, related extended warranty arrangements, and from the sale of cycles in the form of consumable procedure packs, each of which includes consumable CoolGels, CoolLiners, and in the case of the Company's CoolSmooth procedure packs, disposable securement accessories, all of which are used by the Company's customer during treatments. The Company earns revenue from the sale of these products to its customers and to distributors. The Company recognizes revenue when persuasive evidence of an arrangement exists, transfer of title to the customer has occurred, the sales price is fixed or determinable, and collectability is probable. Revenue is deferred in the event that any of the revenue recognition criteria is not met. Each consumable procedure pack includes a disposable computer cartridge that the Company markets as the CoolCard. The CoolCard contains enabling software that permits the Company's customers to perform a fixed number of CoolSculpting procedures, or cycles. This software is not marketed separately from the CoolSculpting system or from the CoolCard. Rather, the functionality that the software provides is part of the overall CoolCard product. The CoolSculpting system is marketed as a non-invasive aesthetic device for the selective reduction of fat, not for its embedded software attributes included in the CoolCard that enable its use. The Company does not provide rights to upgrades and enhancements or post-contract customer support for the embedded software. In addition, the Company does not incur significant software development costs or capitalize its software development costs. Based on this assessment, the Company considers the embedded software in the CoolCard incidental to the CoolCard product as a whole and determined that revenue recognition should not be governed by the provisions of Topic 985 of the FASB Accounting Standards Codification, or ASC. Persuasive Evidence of an Arrangement. The Company uses contracts or customer purchase orders to determine the existence of an arrangement. Delivery . The Company's standard terms specify that title transfers upon shipment to the customer. The Company uses third party shipping documents to verify that title has transferred. Sales Price Fixed or Determinable. The Company assesses whether the sales price is fixed or determinable at the time of the transaction. Sales prices are documented in the executed sales contract or purchase order received prior to shipment. The Company’s standard terms do not allow for trial or evaluation periods, rights of return or refund, payments contingent upon the customer obtaining financing or other terms that could impact the customer’s obligation. Collectability. The Company assesses whether collection is reasonably assured based on a number of factors, including the customer’s past transaction history and credit worthiness. Multiple-Element Arrangements. Typically, all products sold to a customer are delivered at the same time. If a partial delivery occurs as authorized by the customer, the Company allocates revenue to the various products based on their vendor-specific objective evidence of fair value, or VSOE, if VSOE exists according to ASC 605-25 as the basis of determining the relative selling price of each element. If VSOE does not exist, the Company may use third party evidence of fair value, or TPE, to determine the relative selling price of each element. If neither VSOE nor TPE exists, the Company may use management’s best estimate of the sales price, or ESP, of each element to determine the relative selling price. The relative selling prices for control units, applicators, CoolCards and extended warranty are based on established price lists and separate, stand-alone sales of these elements. The Company establishes best estimates within a range of selling prices considering multiple factors including, but not limited to, factors such as size of transaction, pricing strategies and market conditions. The Company believes the use of the ESP allows revenue recognition in a manner consistent with the underlying economics of the transaction. The Company’s products do not require maintenance or support. Additionally, from time to time there may be undelivered elements in a multiple element arrangement, such elements generally being training or extended warranty. The Company defers revenue on undelivered elements of an arrangement and recognizes it once all revenue recognition criteria have been met.
Customer Programs and Payments	Customer Programs and Payments The Company regularly evaluates the adequacy of its estimates for product returns, cooperative marketing arrangements, customer incentive programs and pricing programs. Future market conditions and product transitions may require the Company to take action to change such programs. In addition, when the variables used to estimate these costs change, or if actual costs differ significantly from the estimates, the Company would be required to record incremental increased or reductions to sales, cost of goods sold or operating expenses. If, at any future time, the Company becomes unable to reasonably estimate these costs, recognition of revenue might be deferred until products are sold to users, which would adversely impact sales in the period of transition. Accruals for Customer Programs The Company records an accrued liability for cooperative marketing arrangements and customer incentive programs. The estimated cost of these programs is recorded as a reduction of revenue or as an operating expense, if the Company receives a separately identifiable benefit from the customer and can reasonably estimate the fair value of that benefit. Significant management judgment and estimates must be used to determine the cost of these programs in any accounting period. Cooperative Marketing Arrangements. The Company offers cooperative marketing programs to its North American customers, allowing the customers to receive partial reimbursement for qualifying advertising expenditures which promote the Company's product and brand. Customer participation, as well as reimbursement amounts, is predicated upon purchase levels of CoolCards. The objective of these arrangements is to encourage advertising and promotional events to increase sales of the Company's products. Accruals for these marketing arrangements are recorded at the later of time of sale, or time of commitment, based on the related program parameters, review of related advertising and historical experience. Customer Incentive Programs. The Company's customer incentive program consists of rebates for its distributors based on purchase levels. Estimated costs of customer rebates and similar incentives are recorded at the later of the time the incentive is offered, based on the specific terms and conditions of the program or the time the related revenue is recognized. Customer incentive programs include performance-based incentives and consumer rebates. The Company offers performance-based incentives to its distributor customers, direct partners and indirect partners based on pre-determined performance criteria. Accruals for performance-based incentives are recognized as a reduction of the sale price at the later of the time the incentive is offered, based on the specific terms and conditions of the program or the time the related revenue is recognized. Estimates of required accruals are determined based on negotiated terms, consideration of historical experience, anticipated volume of future purchases, and inventory levels in the channel. Certain incentive programs require management to estimate the number of customers who will actually redeem the incentive based on historical experience and the specific terms and conditions of particular programs. Accounting for Payments to Customers The Company occasionally enters into transactions where it provides consideration to its customers in the forms of cash payments or stock-based awards in exchange for certain goods and services. The Company accounts for such payments to customers in accordance with ASC 605-50, Revenue Recognition: Customer Payments and Incentives, which requires management to characterize the payment as a reduction of revenue if it is unable to demonstrate the receipt of a benefit that is identifiable and sufficiently separable from the revenue transaction and reasonably estimate the fair value of the benefit identified. Significant management judgment and estimates must be used to determine the fair value of the benefit received in any period. For stock awards, the Company believes that the fair value of the awards is more reliably measured than the fair value of the benefit received. The fair value of the stock awards is measured as of the date at which either the commitment for performance by the customer to earn the award is reached or the date the customer’s performance is complete. Until that point is reached, the award is revalued at each reporting period with the true-up to fair value recorded in current period earnings.
Cost of Revenue	Cost of Revenue Cost of revenue consists primarily of cost of finished and semi-finished products purchased from the Company's third-party suppliers, labor, material, and overhead involved in its internal manufacturing processes, technology amortization and royalty fees and cost of product warranty. In the event that a revenue transaction is deferred, the corresponding cost associated with the transaction will also be deferred.
Shipping and Handling	Shipping and Handling Shipping and handling costs charged to customers are recorded as revenue. Shipping costs are included in cost of revenue.
Research and Development	Research and Development Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, and allocated facilities costs for employees and contractors engaged in research, clinical studies, regulatory affairs, and development. The Company expenses all research and development costs in the periods in which they are incurred.
Advertising Costs	Advertising costs The cost of advertising and media is expensed as incurred.
Product Warranties	Product Warranties The Company provides a standard limited warranty on its products of one year for both control units and applicators for its direct customers. For indirect customers in international markets, the Company provides a standard limited warranty on its products of approximately three years for control units and one year for applicators. The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based upon historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. The Company bases product warranty costs on related freight, material, technical support labor and overhead costs. The estimated product warranty costs are assessed by considering historical costs and applying the experienced failure rates to the outstanding warranty period for products sold. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, and average repair costs, including freight, material, technical support labor, and overhead costs, for products returned under warranty. The Company offers an extended warranty on both its CoolSculpting control units and CoolSculpting applicators. The Company recognizes the revenue from the sale of an extended warranty over the extended warranty coverage period.
Stock-Based Compensation	Stock-Based Compensation The Company maintains incentive plans under which incentive and nonqualified stock options are granted primarily to employees and non-employee consultants. Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. The fair value of stock-based awards to employees is estimated using the Black-Scholes option pricing model. The Company estimates its forfeiture rate based on an analysis of its actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate assumption based on actual forfeitures, analysis of employee turnover, and other related factors. Stock-based compensation expense related to stock options granted to non-employees is recognized as the stock options are earned. The awards generally vest ratably over the time period the Company expects to receive services from the non-employee. The fair values attributable to these options are amortized over the service period and the unvested portion of these options is remeasured at each vesting date.
Income Taxes	Income Taxes The Company utilizes the asset and liability method of accounting for income taxes, under which deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse and for operating losses and tax credit carryforwards. The Company estimates its income taxes and amounts ultimately payable or recoverable in multiple tax jurisdictions around the world. Estimates involve interpretations of regulations and are inherently complex. Resolution of income tax treatments in individual jurisdictions may not be known for many years after completion of any fiscal year. The Company is required to evaluate the realizability of its deferred tax assets on an ongoing basis to determine whether there is a need for a valuation allowance with respect to such deferred tax assets. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized. Significant management judgment is required in determining any valuation allowance recorded against deferred tax assets. In evaluating the ability to recover deferred tax assets, the Company considers all available positive and negative evidence giving greater weight to its recent cumulative losses and its ability to carryback losses against prior taxable income and, commensurate with objective verifiability, the forecast of future taxable income including the reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. The Company recognizes and measures uncertain tax positions taken or expected to be taken in a tax return if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such positions are then measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement. The Company reports a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken in a tax return. The Company adjusts these reserves in light of changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the provision for income taxes in the period in which such determination is made. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate, as well as the related net interest. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax provision. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheet. The Company files annual income tax returns in multiple taxing jurisdictions around the world. A number of years may elapse before an uncertain tax position is audited and finally resolved. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its reserves for income taxes reflect the most likely outcome. The Company adjusts these reserves, as well as the related interest, in light of changing facts and circumstances. Settlement of any particular position could require the use of cash or loss of tax attributes.
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) per share of common stock is computed by giving effect to all potentially dilutive securities outstanding during the period, including options, restricted stock units and common stock issuable pursuant to the ESPP.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Accumulated other comprehensive income (loss) includes foreign currency translation adjustments and unrealized gains (losses) on available-for-sale securities net of tax, the impact of which has been excluded from earnings and reflected as components of stockholders' equity.
Foreign currency translation	Foreign currency translation Based on an evaluation of economic facts and circumstances together with the functional currency analysis prescribed in ASC 830, Foreign Currency Matters , on October 1, 2013, the Company changed the functional and reporting currency for its operations in the United Kingdom from the U.S. Dollar to the British Pound. Such change did not have a material impact on the consolidated financial statements of the Company. The functional and reporting currency is the Euro for the Company's operations in Ireland and the U.S. dollar for all of its other foreign operations. All assets and liabilities of the Company's operations in the United Kingdom and Ireland are translated to U.S. Dollars at current period end exchange rates, and revenue and expenses are translated to U.S. Dollars using average exchange rates in effect during the period. The gains and losses from the foreign currency translation of the foreign subsidiaries' financial statements are included as a separate component of stockholders' equity under "Accumulated other comprehensive income (loss)." Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in other income (expense), net.
Recent Accounting Pronouncements	Recent Accounting Pronouncements On May 28, 2014 , the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. On August 12, 2015 , the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delays the effective date of ASU 2014-09 by one year. The objective of this update is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. This standard update contains principles that the Company will apply to determine the measurement of revenue and timing of when it is recognized. This guidance allows for two methods of adoption: (a) full retrospective adoption, meaning the guidance is applied to all periods presented, or (b) modified retrospective adoption, meaning the cumulative effect of applying this guidance is recognized as an adjustment to the fiscal 2018 opening accumulated deficit balance. The Company expects to adopt this guidance effective January 1, 2018 , and is currently evaluating the two adoption methods as well as the impact this new guidance will have on its consolidated financial statements and related disclosures. In August 2014 , the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern. This standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016 . The new guidance is not expected to have an impact on the Company's consolidated financial statements and related disclosures. In April 2015 , the FASB issued Accounting Standards Update No. 2015-05 regarding Subtopic 350-40, “Intangibles - Goodwill and Other - Internal-Use Software.” This standard provides guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, the customer should account for the software license element of the arrangement consistent with other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The amendments are effective for annual and interim periods beginning after December 15, 2015 . Early adoption is permitted. The amendments may be applied either prospectively to all arrangements entered into or materially modified after the effective date or retrospectively. The Company is currently evaluating the impact this new guidance will have on its consolidated financial statements and related disclosures. In June 2015 , the FASB issued Accounting Standards Update No. 2015-10, Technical Corrections and Improvements. The standard covers a wide range of Topics in the Codification. The amendments in this standard represent changes to clarify the Codification, correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost on most entities. The amendments are effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2015 . The Company does not anticipate that the adoption of this standard will have a material impact on its consolidated financial statements and footnote disclosures. The Company is currently evaluating the impact this new guidance will have on its consolidated financial statements and related disclosures. In July 2015 , the FASB issued Accounting Standards Update No. 2015-11 to amend ASC Topic 330, Inventory ("ASC 330") to simplify the measurement of inventory. The amendments require that an entity measure inventory at the lower of cost and net realizable value instead of the lower of cost and market. This guidance is effective for public companies for years, and interim periods within those years, beginning on or after December 15, 2016, with earlier application permitted as of the beginning of an interim or annual reporting period. This guidance will be effective for the Company beginning in its first quarter of fiscal 2017. The Company is currently evaluating the impact this new guidance will have on its consolidated financial statements and related disclosures. In November 2015, the FASB issued Accounting Standards Update No. 2015-17, Income Taxes - Balance Sheet Reclassification of Deferred Taxes (Topic 740). This ASU requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this update. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company early adopted this ASU on a prospective basis in the fourth quarter of 2015 and, as a result, reclassified $40.5 million of current deferred tax assets to long-term assets on the accompanying in consolidated balance sheet as of December 31, 2015. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. This ASU requires lease assets and lease liabilities arising from leases, including operating leases, to be recognized on the balance sheet. ASU 2016-02 will become effective for the Company on January 1, 2019, and requires adoption using a modified retrospective approach. The Company is currently evaluating the impact of this guidance on its consolidated financial statements and related disclosures.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Allowance for Doubtful Accounts	The allowance for doubtful accounts consisted of the following activity for fiscal years ended December 31, 2015 , 2014 and 2013 (in thousands): Description Balance at Beginning of Year Charge to expense Write-offs, net of recoveries Balance at End of Year Year ended December 31, 2013 $ 330 $ 59 $ (389 ) $ — Year ended December 31, 2014 — 469 (145 ) 324 Year ended December 31, 2015 $ 324 $ 1,032 $ (173 ) $ 1,183
Useful Lives of Property and Equipment	The useful lives of the property and equipment are as follows: Lab equipment, tooling, and molds 5 years Computer equipment 3 years Computer software 3 years Furniture and fixtures 5 years Vehicles 5 years Leasehold improvements Shorter of lease term or estimated useful life (1) During fiscal year 2015, the Company determined that the 2014 leasehold improvements category incorrectly contained computer equipment of $0.4 million . The table above has been revised to correctly reflect these assets within the computer equipment category in the 2014 comparable numbers. The Company concluded that this adjustment was not material to the previously issued consolidated financial statements. Property and equipment, net comprised the following (in thousands): December 31, 2015 2014 Lab equipment, tooling and molds $ 3,228 $ 2,766 Computer software 2,019 1,337 Computer equipment (1) 2,757 1,366 Leasehold improvements (1) 1,670 1,070 Furniture and fixtures 950 494 Vehicles 35 35 Total property and equipment 10,659 7,068 Less: Accumulated depreciation and amortization (5,635 ) (4,111 ) Construction in progress 1,945 767 Property and equipment, net $ 6,969 $ 3,724
Components of accumulated other comprehensive income	Components of accumulated other comprehensive loss was as follows (in thousands): December 31, 2015 2014 Cumulative translation adjustments $ (1,615 ) $ (690 ) Unrealized loss on marketable securities, net of tax (21 ) (6 ) Accumulated other comprehensive loss $ (1,636 ) $ (696 )

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair value of financial assets and liabilities by level within fair value hierarchy	The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): As of December 31, 2015 Level 1 Level 2 Level 3 Fair Value Financial Assets Cash equivalents: Money market funds $ 1,342 $ — $ — $ 1,342 Short-term investments: U.S. Agency securities — 1,549 — 1,549 U.S. Treasury — 500 — 500 Corporate bonds — 7,763 — 7,763 Commercial paper — 500 — 500 Certificates of deposit 2,555 — — 2,555 Long-term investments: U.S. Agency securities — 497 — 497 Corporate bonds — 874 — 874 Certificates of deposit 2,119 — — 2,119 Total $ 6,016 $ 11,683 $ — $ 17,699 As of December 31, 2014 Level 1 Level 2 Level 3 Fair Value Financial Assets Cash equivalents: Money market funds $ 6,062 $ — $ — $ 6,062 Short-term investments: U.S. Agency securities — 5,240 — 5,240 U.S. Treasury — 1,004 — 1,004 Corporate bonds — 7,774 — 7,774 Commercial paper — 1,349 — 1,349 Certificates of deposit 919 — — 919 Long-term investments: U.S. Agency securities — 999 — 999 U.S. Treasury — 500 — 500 Corporate bonds — 750 — 750 Certificates of deposit 2,556 — — 2,556 Total $ 9,537 $ 17,616 $ — $ 27,153

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Investments	The Company's short-term and long-term investments as of December 31, 2015 are as follows (in thousands): Short-term Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Agency securities $ 1,551 $ — $ (2 ) $ 1,549 U.S. Treasury 500 — — 500 Corporate bonds 7,776 — (13 ) 7,763 Commercial paper 500 — — 500 Certificates of deposit 2,555 — — 2,555 Total $ 12,882 $ — $ (15 ) $ 12,867 Long-term Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Agency securities $ 499 $ — $ (2 ) $ 497 U.S. Treasury — — — — Corporate bonds 878 — (4 ) 874 Certificates of deposit 2,119 — — 2,119 Total $ 3,496 $ — $ (6 ) $ 3,490 The Company's short-term and long-term investments as of December 31, 2014 are as follows (in thousands): Short-term Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Agency securities $ 5,240 $ 1 $ (1 ) $ 5,240 U.S. Treasury 1,003 1 — 1,004 Corporate bonds 7,778 2 (6 ) 7,774 Commercial paper 1,349 — — 1,349 Certificates of deposit 919 — — 919 Total $ 16,289 $ 4 $ (7 ) $ 16,286 Long-term Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. Agency securities $ 1,000 $ — $ (1 ) $ 999 U.S. Treasury 500 — — 500 Corporate bonds 752 — (2 ) 750 Certificates of deposit 2,556 — — 2,556 Total $ 4,808 $ — $ (3 ) $ 4,805
Schedule of Contractual Maturities of Investments	The contractual maturities of the Company's short-term and long-term investments as of December 31, 2015 are as follows (in thousands): December 31, 2015 Amortized Cost Fair Value Due in one year or less $ 12,882 $ 12,867 Due in one year to five years 3,496 3,490 $ 16,378 $ 16,357
Schedule of Inventory	The components of inventory consist of the following (in thousands): December 31, 2015 2014 Raw materials $ 9,117 $ 7,692 Finished goods 18,978 7,844 Total inventory $ 28,095 $ 15,536
Schedule of Property and Equipment	The useful lives of the property and equipment are as follows: Lab equipment, tooling, and molds 5 years Computer equipment 3 years Computer software 3 years Furniture and fixtures 5 years Vehicles 5 years Leasehold improvements Shorter of lease term or estimated useful life (1) During fiscal year 2015, the Company determined that the 2014 leasehold improvements category incorrectly contained computer equipment of $0.4 million . The table above has been revised to correctly reflect these assets within the computer equipment category in the 2014 comparable numbers. The Company concluded that this adjustment was not material to the previously issued consolidated financial statements. Property and equipment, net comprised the following (in thousands): December 31, 2015 2014 Lab equipment, tooling and molds $ 3,228 $ 2,766 Computer software 2,019 1,337 Computer equipment (1) 2,757 1,366 Leasehold improvements (1) 1,670 1,070 Furniture and fixtures 950 494 Vehicles 35 35 Total property and equipment 10,659 7,068 Less: Accumulated depreciation and amortization (5,635 ) (4,111 ) Construction in progress 1,945 767 Property and equipment, net $ 6,969 $ 3,724
Schedule of Accrued Liabilities	The following table shows the components of accrued liabilities (in thousands): December 31, 2015 2014 Accrued payroll and employee related expenses $ 14,887 $ 8,386 Accrued marketing expenses 5,554 2,959 Accrued royalty 5,453 3,612 Sales and other taxes payable 3,703 2,123 Advance payments from customers 1,585 1,908 Accrued legal expenses 1,465 592 Accrued warranty 527 569 Other 1,517 1,301 Total accrued and other current liabilities $ 34,691 $ 21,450
Schedule of Deferred Revenue	Changes in the Company's deferred revenue, including long-term deferred revenue, related to extended warranties were as follows (in thousands): Year Ended December 31, 2015 2014 Balance at the beginning of the period $ 3,272 $ 1,443 Extended warranties issued 3,158 3,897 Amortization (3,528 ) (2,068 ) Balance at the end of the period $ 2,902 $ 3,272 The following table shows the components of deferred revenue, including long-term deferred revenue (in thousands): December 31, 2015 2014 Deferred revenue $ 1,347 $ 573 Deferred extended warranty revenue 2,902 3,272 Deferred training revenue 3,115 1,381 Other deferred revenue 544 465 Total deferred revenue $ 7,908 $ 5,691
Schedule of Product Warranty Accrual	The estimated product warranty accrual was as follows (in thousands): Year Ended December 31, 2015 2014 Balance at the beginning of the period $ 569 $ 676 Settlement of pre-existing warranties (658 ) (772 ) Provision 616 665 Balance at the end of the period $ 527 $ 569

License Agreement With Massac28

License Agreement With Massachusetts General Hospital (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The intangible asset, net comprised the following (in thousands): December 31, December 31, Purchased technology $ 8,050 $ 8,050 Less: Accumulated amortization (2,958 ) (2,270 ) Intangible asset, net $ 5,092 $ 5,780
Schedule of Estimated Future Amortization Expense of Intangible Assets	The total estimated annual future amortization expense of this intangible asset as of December 31, 2015 , is as follows (in thousands): Year ending December 31, 2016 $ 650 2017 650 2018 650 2019 650 2020 650 Thereafter 1,842 Total $ 5,092

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease payments under the non-cancellable operating leases as of December 31, 2015 , are as follows (in thousands): Year Ending December 31, Amount 2016 $ 2,344 2017 2,058 2018 1,912 2019 763 2020 234 Total future minimum lease payments $ 7,311
Schedule of Capital Leased Assets	Property and equipment includes the following amounts under leases that have been capitalized as of December 31, 2015 and 2014 were as follows (in thousands): Useful life (Years) December 31, December 31, Computer equipment 3 $ 382 $ 382 Total capital leased equipment 382 382 Less: Accumulated depreciation and amortization (149 ) (21 ) Capital leased equipment, net $ 233 $ 361
Schedule of Future Minimum Lease Payments Required Under Capital Leases	Future minimum payments required under capital leases as of December 31, 2015 , are as follows (in thousands): Year Ending December 31, Amount 2016 $ 132 2017 141 Total future payments $ 273 Less: Amount representing interest $ 11 Present value of future minimum payments 262 Less: Current portion 124 Long term portion $ 138

Stock-Based Compensation Plans

Stock-Based Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Activity	A summary of share-based awards available for grant is as follows: Years Ended December 31, 2015 December 31, 2014 December 31, 2013 Balance at beginning of fiscal year 2,685,209 1,086,737 1,103,836 Additional shares reserved 1,000,000 1,851,794 1,200,000 Options granted (45,622 ) (255,000 ) (568,987 ) Restricted stock units granted (593,003 ) (508,729 ) (1,205,200 ) Options canceled 37,520 41,681 307,738 Restricted stock units canceled 174,094 157,358 163,689 Restricted stock unit withheld for tax 259,107 311,368 85,661 Balance at end of fiscal year 3,517,305 2,685,209 1,086,737 Stock Option Awards A summary of the stock option activity is as follows: Options Outstanding Number of Weighted- Weighted-Average Remaining Contractual Life (in Years) Aggregate Intrinsic Value (in thousands) Balance, December 31, 2012 4,128,334 4 $ 4.96 Options granted 568,987 6.60 Options exercised (791,198 ) 3.34 Options canceled (307,738 ) 7.36 Balance, December 31, 2013 3,598,385 $ 5.36 Options granted 255,000 18.42 Options exercised (569,283 ) 4.89 Options canceled (41,681 ) 5.50 Balance, December 31, 2014 3,242,421 $ 6.47 Options granted 45,622 34.65 Options exercised (608,931 ) 6.79 Options canceled (37,520 ) 8.55 Balance, December 31, 2015 2,641,592 $ 6.86 6.81 $ 57,532 Vested and expected to vest, December 31, 2015 2,620,217 $ 6.80 6.81 $ 57,187 Vested and Exercisable, December 31, 2015 2,127,228 $ 6.22 6.72 $ 47,457
Summary of Stock Options Outstanding by Exercise Price Range	The following table summarizes information about stock options outstanding as of December 31, 2015 : Options Outstanding Exercise Price Stock Options Outstanding Weighted-Average Remaining Contractual Life (in Years) Options Exercisable $0.55-4.60 278,755 6.6 185,111 4.62-4.62 90,000 6.9 55,625 5.04-5.04 1,431,092 6.6 1,252,213 5.06-6.34 295,572 6.9 242,576 6.38-10.20 287,135 6.5 240,224 11.30-17.44 56,229 7.4 32,267 17.48-17.48 90,000 8.4 90,000 20.88-20.88 47,187 8.1 20,105 21.00-21.00 20,000 8.2 9,167 $34.65-34.65 45,622 9.1 — 2,641,592 2,127,288
Restricted Stock Activity	Activity related to restricted stock units and awards is set forth below: Number of Units and Awards Weighted- Balance, December 31, 2012 1,157,450 $ 5.38 Restricted stock units granted 1,205,200 5.57 Restricted stock units released (292,265 ) 5.35 Restricted stock units canceled (163,689 ) 4.31 Balance, December 31, 2013 1,906,696 $ 5.60 Restricted stock units granted 508,729 19.99 Restricted stock units released (724,986 ) 6.03 Restricted stock units canceled (157,358 ) 6.50 Balance, December 31, 2014 1,533,081 $ 10.08 Restricted stock units granted 593,003 31.96 Restricted stock units released (639,339 ) 10.76 Restricted stock units canceled (174,094 ) 14.16 Balance, December 31, 2015 1,312,651 $ 19.09
Stock-Based Compensation Expense	Stock-based compensation related to all of the Company's stock-based awards and employee stock purchases was recorded as an expense or a reduction to revenue and allocated as follows (in thousands): Year Ended December 31, 2015 2014 2013 Revenue $ 205 $ 833 $ — Cost of revenue 744 443 248 Research and development 1,619 1,073 1,645 Sales and marketing 5,129 2,917 1,783 General and administrative 5,522 4,117 2,984 Total stock-based compensation $ 13,219 $ 9,383 $ 6,660
Summary of Fair Value of Employee Stock Option Assumptions	The fair value of employee stock options was estimated using the following weighted-average assumptions: Year Ended December 31, 2015 2014 2013 Expected term (in years) 4.8 4.4 4.8 Expected volatility 63 % 43 % 51 % Risk-free interest rate 1.29 % 1.25 % 1.02 % Expected dividend yield 0 % 0 % 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Domestic and Foreign Income (Loss) before Income Taxes	The domestic and foreign components of income (loss) before income taxes were as follows (in thousands): Year Ended December 31, 2015 2014 2013 Domestic $ 14,065 $ 1,443 $ (19,535 ) Foreign (10,733 ) 319 370 Income (loss) before income taxes $ 3,332 $ 1,762 $ (19,165 )
Schedule of Components of Income Tax Expense	Provision for (benefit from) income taxes consisted of the following (in thousands): Year Ended December 31, 2015 2014 2013 Current provision: Federal $ 654 $ — $ — State 1,098 156 60 Foreign 183 94 61 Total current 1,935 250 121 Deferred provision (benefit): Federal (34,835 ) — — State (5,576 ) — — Foreign 6 (19 ) 19 Total deferred (40,405 ) (19 ) 19 Total provision for (benefit from) income taxes $ (38,470 ) $ 231 $ 140
Schedule of Effective Income Tax Rate Reconciliation	The following is a reconciliation of the statutory federal income tax rate to the Company's effective tax: Year Ended December 31, 2015 2014 2013 Tax at federal statutory rate 35 % 35 % 35 % State income taxes, net of federal benefit 5 6 2 Non-deductible permanent difference 16 22 (1 ) Non-deductible executive compensation 51 150 — Change in valuation allowance (1,394 ) (157 ) (34 ) Research and development credits (36 ) (47 ) (2 ) Stock-based compensation 11 6 (1 ) Impact of foreign operations 153 (2 ) — Other tax adjustment 4 — — Effective tax rate (1,155 )% 13 % (1 )%
Schedule of Deferred Tax Assets	Tax effects of temporary differences that give rise to significant portions of the deferred tax assets are presented below (in thousands): December 31, 2015 2014 Net operating loss carryforwards $ 19,829 $ 31,237 Income tax credits 5,867 4,838 Other Tax Credit 851 — Depreciation and amortization 4,855 5,615 Accruals and reserves 7,606 4,316 Stock-based compensation 3,950 2,790 Total deferred tax assets 42,958 48,796 Valuation allowance (2,483 ) (48,730 ) Net deferred tax assets $ 40,475 $ 66
Summary of Valuation Allowance	The valuation allowance for deferred tax assets consisted of the following activity for the fiscal years ended December 31, 2015, 2014 and 2013 (in thousands): Description Balance at Beginning of Year Additions Deductions Balance at End of Year Year ended December 31, 2013 $ 44,926 $ 6,077 $ — $ 51,003 Year ended December 31, 2014 51,003 1,011 (3,284 ) 48,730 Year ended December 31, 2015 $ 48,730 $ 673 $ (46,920 ) (1) $ 2,483 (1) Of this deduction, $40.4 million relates to the release in the valuation allowance, which was recorded as a deferred tax benefit during the year.
Summary of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Balance as of January 1, 2013 $ 902 Gross increase on tax positions related to the prior year 1,434 Gross increase on tax positions related to the current year 589 Balance as of December 31, 2013 2,925 Gross decrease on tax positions related to the prior year (1,746 ) Gross increase (decrease) on tax positions related to the current year 274 Balance as of December 31, 2014 1,453 Gross increase on tax positions related to the prior year 99 Gross increase on tax positions related to the current year 1,341 Balance as of December 31, 2015 $ 2,893

Net Income (Loss) per Share o32

Net Income (Loss) per Share of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net income (loss) per share is as follows: Year Ended December 31, 2015 2014 2013 Numerator Net income (loss) (in thousands) $ 41,802 $ 1,531 $ (19,305 ) Denominator Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic 38,754,643 37,563,590 36,209,051 Dilutive effect of incremental shares and share equivalents 2,041,003 3,433,382 — Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted 40,795,646 40,996,972 36,209,051 Net income (loss) per share: Net income (loss) per share, basic $ 1.08 $ 0.04 $ (0.53 ) Net income (loss) per share, diluted $ 1.02 $ 0.04 $ (0.53 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding potentially dilutive securities were excluded from the computation of diluted net income (loss) per share of common stock for the periods presented, because including them would have been anti-dilutive: Year Ended December 31, 2015 2014 2013 Options to purchase common stock 39,497 220,712 3,598,385 Restricted stock units 26,290 12,723 1,906,696 Common stock issuable pursuant to the ESPP — — 86,026 Total 65,787 233,435 5,591,107

Supplemental Cash Flow Inform33

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	The supplemental cash flow information consists of the following (in thousands): Year Ended December 31, 2015 2014 2013 Cash paid for interest $ 13 $ — $ — Cash paid for income taxes $ 38 $ 285 $ 188 Non-cash investing and financing activities: Assets acquired under capital leases $ — $ (382 ) $ — Accounts payable and accrued liabilities related to property, plant and equipment purchases $ 843 $ 106 $ 14

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Revenue By Geographic Region	The Company’s revenue by geographic region, based on the location to where the product was shipped, is summarized as follows (in thousands): Year Ended December 31, 2015 2014 2013 North America $ 193,376 $ 134,434 $ 89,150 International 62,040 40,044 22,476 Total $ 255,416 $ 174,478 $ 111,626
Revenue By Product	The following table sets forth revenue by product expressed as dollar amounts (in thousands): Year Ended December 31, 2015 2014 2013 System revenue $ 130,698 $ 93,015 $ 61,359 Consumable revenue 124,718 81,463 50,267 Total $ 255,416 $ 174,478 $ 111,626

Supplementary Financial Data 35

Supplementary Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table presents selected unaudited consolidated financial data for each of the eight quarters in the two-year period ended December 31, 2015 . The selected quarterly financial data should be read in conjunction with the Company's consolidated financial statements and the related notes and "Item 7: Management's Discussion and Analysis of Financial Condition and Results of Operations." This information has been derived from the Company's unaudited consolidated financial statements that, in management's opinion, reflect all recurring adjustments necessary to fairly state this information when read in conjunction with the Company's consolidated financial statements and the related notes appearing in the section entitled "Consolidated Financial Statements," Net income (loss) per share-basic and diluted, for the four quarters of each fiscal year may not sum to the total for the fiscal year because of the different number of shares outstanding during each period. The results of operations for any quarter are not necessarily indicative of the results to be expected for any future period. (In thousands, except share and per share data) Quarter First Second Third Fourth (1) Year Ended December 31, 2015 Total revenue $ 51,558 $ 64,431 $ 61,202 $ 78,225 Gross profit $ 37,180 $ 46,315 $ 45,161 $ 52,385 Net income (loss) $ (2,129 ) $ 1,178 $ 2,147 $ 40,606 Net income (loss) per share, basic $ (0.06 ) $ 0.03 $ 0.06 $ 1.04 Shares used in calculation-basic 38,383,022 38,649,873 38,881,183 39,093,825 Net income (loss) per share, diluted $ (0.06 ) $ 0.03 $ 0.05 $ 0.99 Shares used in calculation-diluted 38,383,022 41,641,660 40,860,593 40,966,744 Quarter First Second Third Fourth Year Ended December 31, 2014 Total revenue $ 30,975 $ 47,061 $ 45,670 $ 50,772 Gross profit $ 21,959 $ 33,401 $ 33,115 $ 35,939 Net income (loss) $ (7,337 ) $ 2,769 $ 4,782 $ 1,317 Net income (loss) per share, basic $ (0.20 ) $ 0.07 $ 0.13 $ 0.03 Shares used in calculation-basic 37,215,697 37,440,537 37,630,222 37,958,395 Net income (loss) per share, diluted $ (0.20 ) $ 0.07 $ 0.12 $ 0.03 Shares used in calculation-diluted 37,215,697 40,597,275 40,926,034 41,434,178 (1) In the fourth quarter of fiscal 2015, the Company released $40.4 million of its deferred tax asset valuation allowance. See Note 11 to the Consolidated Financial Statements.

The Company and Basis of Pres36

The Company and Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of revenue					$ 74,375	$ 50,064	$ 34,189
Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue reduction				$ (700)
Restatement Adjustment [Member] | Adjustment Related to Fiscal Year 2013 [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenue reduction				$ (400)
Overstatement of Inventory and Understatement of Cost of Revenue [Member] | Restatement Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of revenue			$ 200
Overstatement of Inventory and Understatement of Cost of Revenue [Member] | Restatement Adjustment [Member] | Adjustment Related to Fiscal 2012 [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of revenue			100
Overstatement of Inventory and Understatement of Cost of Revenue [Member] | Restatement Adjustment [Member] | Adjustment Related to Fiscal 2013 [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of revenue			23
Overstatement of Inventory and Understatement of Cost of Revenue [Member] | Restatement Adjustment [Member] | Adjustment Related to Fiscal 2014 [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of revenue			$ 42
Overstatement of Inventory and Understatement of Cost of Revenue [Member] | Scenario, Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of revenue	$ 300	$ 200

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Restricted cash	$ 452,000	$ 560,000
Asset Impairment Charges	0
Advertising expense	17,400,000	7,900,000	$ 8,900,000
Foreign currency transaction gains (losses)	(300,000)	(300,000)	$ 24,000
Long-term deferred tax assets	$ 40,475,000	$ 0

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Concentration Of Credit Risk (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance at Beginning of Year	$ 324,000	$ 0	$ 330,000
Additions	1,032,000	469,000	59,000
Reductions	(173,000)	(145,000)	(389,000)
Balance at End of Year	$ 1,183,000	$ 324,000	$ 0
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Allowance for Doubtful Accounts Receivable [Roll Forward]
Concentration risk, percentage	10.00%	24.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Allowance for Doubtful Accounts Receivable [Roll Forward]
Concentration risk, percentage	10.00%

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Property Plant And Equipment (Details)	12 Months Ended
	Dec. 31, 2015
Lab Equipment, Tooling, and Molds [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property, plant and equipment	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property, plant and equipment	3 years
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property, plant and equipment	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property, plant and equipment	5 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property, plant and equipment	5 years
Capitalized Software [Member]
Property, Plant and Equipment [Line Items]
Useful lives of property, plant and equipment	3 years

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Warranty (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Product Liability Contingency [Line Items]
Deferred Revenue	$ 3.5	$ 2.1	$ 1
Direct Customer [Member] | Control Units [Member]
Product Liability Contingency [Line Items]
Product warranty term	1 year
Direct Customer [Member] | Applicators [Member]
Product Liability Contingency [Line Items]
Product warranty term	1 year
International [Member] | Indirect Customer [Member] | Control Units [Member]
Product Liability Contingency [Line Items]
Product warranty term	3 years
International [Member] | Indirect Customer [Member] | Applicators [Member]
Product Liability Contingency [Line Items]
Product warranty term	1 year

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Cumulative translation adjustments	$ (1,615)	$ (690)
Unrealized loss on marketable securities, net of tax	(21)	(6)
Accumulated other comprehensive loss	$ (1,636)	$ (696)

Fair Value of Financial Instr42

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	$ 16,357
Financial assets total	17,699	$ 27,153
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets total	6,016	9,537
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets total	11,683	17,616
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets total	0	0
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, fair value	1,342	6,062
Money Market Funds [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, fair value	1,342	6,062
Money Market Funds [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, fair value	0	0
Money Market Funds [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents, fair value	0	0
Short-term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	12,867	16,286
Short-term Investments [Member] | U.S. Agency Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	1,549	5,240
Short-term Investments [Member] | U.S. Agency Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | U.S. Agency Securities [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	1,549	5,240
Short-term Investments [Member] | U.S. Agency Securities [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | U.S. Treasury [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	500	1,004
Short-term Investments [Member] | U.S. Treasury [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | U.S. Treasury [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	500	1,004
Short-term Investments [Member] | U.S. Treasury [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	7,763	7,774
Short-term Investments [Member] | Corporate Bonds [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | Corporate Bonds [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	7,763	7,774
Short-term Investments [Member] | Corporate Bonds [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	500	1,349
Short-term Investments [Member] | Commercial Paper [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | Commercial Paper [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	500	1,349
Short-term Investments [Member] | Commercial Paper [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	2,555	919
Short-term Investments [Member] | Certificates of Deposit [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	2,555	919
Short-term Investments [Member] | Certificates of Deposit [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Short-term Investments [Member] | Certificates of Deposit [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Long-term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	3,490	4,805
Long-term Investments [Member] | U.S. Agency Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	497	999
Long-term Investments [Member] | U.S. Agency Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Long-term Investments [Member] | U.S. Agency Securities [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	497	999
Long-term Investments [Member] | U.S. Agency Securities [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Long-term Investments [Member] | U.S. Treasury [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	500
Long-term Investments [Member] | U.S. Treasury [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities		0
Long-term Investments [Member] | U.S. Treasury [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities		500
Long-term Investments [Member] | U.S. Treasury [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities		0
Long-term Investments [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	874	750
Long-term Investments [Member] | Corporate Bonds [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Long-term Investments [Member] | Corporate Bonds [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	874	750
Long-term Investments [Member] | Corporate Bonds [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Long-term Investments [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	2,119	2,556
Long-term Investments [Member] | Certificates of Deposit [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	2,119	2,556
Long-term Investments [Member] | Certificates of Deposit [Member] | Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	0	0
Long-term Investments [Member] | Certificates of Deposit [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, fair value sale securities	$ 0	$ 0

Balance Sheet Components - Inve

Balance Sheet Components - Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 16,378
Fair Value	16,357
Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	12,882	$ 16,289
Gross Unrealized Gains	0	4
Gross Unrealized Losses	(15)	(7)
Fair Value	12,867	16,286
Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	3,496	4,808
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(6)	(3)
Fair Value	3,490	4,805
U.S. Agency Securities [Member] | Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,551	5,240
Gross Unrealized Gains	0	1
Gross Unrealized Losses	(2)	(1)
Fair Value	1,549	5,240
U.S. Agency Securities [Member] | Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	499	1,000
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(2)	(1)
Fair Value	497	999
U.S. Treasury [Member] | Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	500	1,003
Gross Unrealized Gains	0	1
Gross Unrealized Losses	0	0
Fair Value	500	1,004
U.S. Treasury [Member] | Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	0	500
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	0	500
Corporate Bonds [Member] | Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	7,776	7,778
Gross Unrealized Gains	0	2
Gross Unrealized Losses	(13)	(6)
Fair Value	7,763	7,774
Corporate Bonds [Member] | Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	878	752
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(4)	(2)
Fair Value	874	750
Commercial Paper [Member] | Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	500	1,349
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	500	1,349
Certificates of Deposit [Member] | Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,555	919
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	2,555	919
Certificates of Deposit [Member] | Long-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,119	2,556
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$ 2,119	$ 2,556

Balance Sheet Components - In44

Balance Sheet Components - Investments, Contractual Maturities (Details) $ in Thousands	Dec. 31, 2015USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Amortized Cost, Due in one year or less	$ 12,882
Amortized Cost, Due in one year to five years	3,496
Amortized Cost	16,378
Fair Value, Due in one year or less	12,867
Fair Value, Due in one year to five years	3,490
Fair Value	$ 16,357

Balance Sheet Components - In45

Balance Sheet Components - Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Raw materials	$ 9,117	$ 7,692
Finished goods	18,978	7,844
Total inventory	$ 28,095	$ 15,536

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 10,659	$ 7,068
Less: Accumulated depreciation and amortization	(5,635)	(4,111)
Property and equipment, net	6,969	3,724
Depreciation	1,700	1,100	$ 1,000
Lab Equipment, Tooling and Molds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,228	2,766
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,019	1,337
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,757	1,366
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,670	1,070
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	950	494
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	35	35
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,945	767
Scenario, Previously Reported [Member] | Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 400

Balance Sheet Components - Accr

Balance Sheet Components - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and employee related expenses	$ 14,887	$ 8,386
Accrued marketing expenses	5,554	2,959
Accrued royalty	5,453	3,612
Sales and other taxes payable	3,703	2,123
Advance payments from customers	1,585	1,908
Accrued legal expenses	1,465	592
Accrued warranty	527	569
Other	1,517	1,301
Total accrued and other current liabilities	$ 34,691	$ 21,450

Balance Sheet Components Balanc

Balance Sheet Components Balance Sheet Components - Deferred Revenues (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Revenue Disclosure [Abstract]
Deferred revenue	$ 1,347	$ 573
Deferred extended warranty revenue	2,902	3,272
Deferred training revenue	3,115	1,381
Other deferred revenue	544	465
Total deferred revenue	$ 7,908	$ 5,691

Balance Sheet Components - Warr

Balance Sheet Components - Warranty (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Movement in Extended Product Warranty Accrual [Roll Forward]
Balance at the beginning of the period	$ 3,272	$ 1,443
Extended warranties issued	3,158	3,897
Amortization	(3,528)	(2,068)
Balance at the end of the period	2,902	3,272
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at the beginning of the period	569	676
Settlement of pre-existing warranties	(658)	(772)
Provision	616	665
Balance at the end of the period	$ 527	$ 569

License Agreement With Massac50

License Agreement With Massachusetts General Hospital (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2011	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2010
Acquired Finite-Lived Intangible Assets [Line Items]
Period that agreement remains in full force after last commercial sale with royalty due			1 year
Period to terminate contract with written notice			90 days
Royalty expense, percent of net sales	3.00%
Payments to Acquire Intangible Assets						$ 1.1
Amortization of intangible assets			$ 0.7	$ 0.7	$ 0.7
License Agreement Milestone 1 [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets		$ 1
Cumulative net sales required for milestone payment		70
License Agreement Milestone 2 [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets		6
Cumulative net sales required for milestone payment		$ 200
CoolSculpting
Acquired Finite-Lived Intangible Assets [Line Items]
Royalty expense, percent of net sales			7.00%
Treatment of Acne and Related Skin Conditions
Acquired Finite-Lived Intangible Assets [Line Items]
Royalty expense, percent of net sales	3.00%

License Agreement With Massac51

License Agreement With Massachusetts General Hospital - Intangible Asset, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Purchased technology	$ 8,050	$ 8,050
Less: Accumulated amortization	(2,958)	(2,270)
Intangible asset, net	$ 5,092	$ 5,780

License Agreement With Massac52

License Agreement With Massachusetts General Hospital - Estimated Annual Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
2,016	$ 650
2,017	650
2,018	650
2,019	650
2,020	650
Thereafter	1,842
Intangible asset, net	$ 5,092	$ 5,780

Related Party Transactions - Br

Related Party Transactions - Brazilian Distribution Agreement (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Related Party Transaction, Payment Terms, Maximum Period	180 days
Distributor [Member]
Related Party Transaction [Line Items]
Revenue from related parties	$ 3.6	$ 1.9	$ 1.6
Accounts receivable, related parties	$ 1.7	0.2
Restatement Adjustment [Member] | Sales Revenue, Net [Member]
Related Party Transaction [Line Items]
Revenue from related parties		$ (0.2)	$ (0.7)

Commitments and Contingencies -

Commitments and Contingencies - Operating Lease Commitments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)lease	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Commitments and Contingencies Disclosure [Abstract]
Number of operating leases extended | lease	2
Rent expense	$ 2,500	$ 1,500	$ 1,400
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,016	2,344
2,017	2,058
2,018	1,912
2,019	763
2,020	234
Total future minimum lease payments	$ 7,311

Commitments and Contingencies55

Commitments and Contingencies - Capital Lease Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Capital Leased Assets [Line Items]
Total capital leased equipment	$ 382	$ 382
Less: Accumulated depreciation and amortization	(149)	(21)
Capital leased equipment, net	233	361
Amortization of assets acquired under capital leases	100	21
Future minimum payments under capital leases
2,016	132
2,017	141
Total future payments	273
Less: Amount representing interest	11
Present value of future minimum payments	262
Less: Current portion	124	120
Long term portion	$ 138	262
Computer Equipment [Member]
Capital Leased Assets [Line Items]
Capital leased assets, useful life	3 years
Total capital leased equipment	$ 382	$ 382

Commitments and Contingencies56

Commitments and Contingencies - Purchase Commitments (Details) $ in Millions	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase obligation	$ 5.9

Commitments and Contingencies57

Commitments and Contingencies - Unrecognized Tax Benefits (Details) $ in Millions	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Unrecognized tax benefits	$ 0.3

Commitments and Contingencies58

Commitments and Contingencies - Product Liability Contingencies (Details) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
Self-insured product liability claims paid	$ 0.7
Self insured product warranty liability	$ 1.1

Commitments and Contingencies59

Commitments and Contingencies - Severance (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Loss Contingencies [Line Items]
Stock-based compensation expense due to modification	$ 0	$ 0	$ 700,000
Management [Member]
Loss Contingencies [Line Items]
Termination benefits	0	0	300,000
Stock-based compensation expense due to modification	$ 0	$ 0	$ 700,000

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred Stock (Details) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2011
Equity [Abstract]
Preferred stock, shares authorized	50,000,000	50,000,000	50,000,000
Preferred stock, par value (dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - Common Stock [Member]	12 Months Ended
	Dec. 31, 2015vote$ / shares
Class of Stock [Line Items]
Number of votes per share | vote	1
Dividends declared per share	$ 0
Dividends paid per share	$ 0

Stock-Based Compensation Plan62

Stock-Based Compensation Plans (Details)	12 Months Ended
	Dec. 31, 2015purchase_period$ / sharesshares	Dec. 31, 2014shares	Dec. 31, 2013shares	Dec. 31, 2012shares	Apr. 30, 2012shares	Sep. 30, 2011shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares reserved for future purchase under plan (shares)	1,000,000	1,851,794	1,200,000
Shares reserved for future issuance	3,517,305	2,685,209	1,086,737	1,103,836
2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock available for issuance (shares)						89,234
Increase in shares at each annual anniversary, percent	5.00%
2012 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock available for issuance (shares)					1,500,000
2011 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Offering Periods | purchase_period	1
Percentage of stock purchase price	85.00%
Common stock available for issuance (shares)						470,018
Increase in shares at each annual anniversary, percent	1.00%
Additional shares reserved for future purchase under plan (shares)		370,358
Shares purchased	108,552
Weighted average exercise price of shares purchased (in dollars per share) | $ / shares	$ 22.96
Shares reserved for future issuance	456,835
Performance Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding	34,938
ISO and NSO [Member] | 2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
ISO and NSO [Member] | 2011 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period options may be granted	10 years
ISO and NSO [Member] | 2011 Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of stock purchase price	100.00%
ISO and NSO [Member] | 2012 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
ISO and NSO [Member] | 2012 Stock Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period options may be granted	10 years
ISO and NSO [Member] | 2012 Stock Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of stock purchase price	100.00%
ISO [Member] | 10% Stockholder [Member] | 2011 Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of stock purchase price	110.00%
ISO [Member] | 10% Stockholder [Member] | 2012 Stock Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of stock purchase price	110.00%

Stock-Based Compensation Plan63

Stock-Based Compensation Plans - Stock-based Compensation Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]
Balance at beginning of period (shares)	2,685,209	1,086,737	1,103,836
Additional shares reserved (shares)	1,000,000	1,851,794	1,200,000
Options granted (shares)	(45,622)	(255,000)	(568,987)
Restricted stock units granted (shares)	(593,003)	(508,729)	(1,205,200)
Options canceled (shares)	37,520	41,681	307,738
Restricted stock units canceled (shares)	174,094	157,358	163,689
Restricted stock units withheld for tax (shares)	259,107	311,368	85,661
Balance at end of period (shares)	3,517,305	2,685,209	1,086,737
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Balance at beginning of period (shares)	3,242,421	3,598,385	4,128,334
Options granted (shares)	45,622	255,000	568,987
Options exercised (shares)	(608,931)	(569,283)	(791,198)
Options canceled (shares)	(37,520)	(41,681)	(307,738)
Balance at end of period (shares)	2,641,592	3,242,421	3,598,385
Vested and expected to vest, end of period (shares)	2,620,217
Exercisable, end of period, Shares	2,127,228
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Balance at beginning of period, weighted-average exercise price (per share)	$ 6.47	$ 5.36	$ 4.96
Options granted, period, weighted-average exercise price (per share)	34.65	18.42	6.60
Options exercised, period, weighted-average exercise price (per share)	6.79	4.89	3.34
Options canceled, period, weighted-average exercise price (per share)	8.55	5.50	7.36
Balance at ending of period, weighted-average exercise price (per share)	6.86	$ 6.47	$ 5.36
Vested and expected to vest, end of period, period, weighted-average exercise price (per share)	6.80
Exercisable, end of period, period, weighted-average exercise price (per share)	$ 6.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Balance at end of period, weighted-average remaining contractual life	6 years 9 months 22 days
Balance at end of period, aggregate intrinsic value	$ 57,532
Vested and expected to vest, end of period, weighted-average remaining contractual life	6 years 9 months 22 days
Vested and expected to vest, end of period, aggregate intrinsic value	$ 57,187
Exercisable, end of period, weighted-average remaining contractual life	6 years 8 months 19 days
Exercisable, end of period, aggregate intrinsic value	$ 47,457
Restricted stock units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward]
Restricted stock units granted (shares)	(593,003)	(508,729)	(1,205,200)
Restricted stock units canceled (shares)	174,094	157,358	163,689
Restricted stock units withheld for tax (shares)	259,107	311,368	85,661

Stock-Based Compensation Plan64

Stock-Based Compensation Plans - Stock Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options outstanding	2,641,592
Options exercisable	2,127,288
$0.55-4.60 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 0.55
Exercise price, upper limit (in dollars per share) | $ / shares	$ 4.60
Stock options outstanding	278,755
Weighted-average remaining contractual life	6 years 7 months 6 days
Options exercisable	185,111
4.62-4.62 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 4.62
Exercise price, upper limit (in dollars per share) | $ / shares	$ 4.62
Stock options outstanding	90,000
Weighted-average remaining contractual life	6 years 10 months 24 days
Options exercisable	55,625
5.04-5.04 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 5.04
Exercise price, upper limit (in dollars per share) | $ / shares	$ 5.04
Stock options outstanding	1,431,092
Weighted-average remaining contractual life	6 years 7 months 6 days
Options exercisable	1,252,213
5.06-6.34 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 5.06
Exercise price, upper limit (in dollars per share) | $ / shares	$ 6.34
Stock options outstanding	295,572
Weighted-average remaining contractual life	6 years 10 months 24 days
Options exercisable	242,576
6.38-10.20 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 6.38
Exercise price, upper limit (in dollars per share) | $ / shares	$ 10.20
Stock options outstanding	287,135
Weighted-average remaining contractual life	6 years 6 months
Options exercisable	240,224
11.30-17.44 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 11.30
Exercise price, upper limit (in dollars per share) | $ / shares	$ 17.44
Stock options outstanding	56,229
Weighted-average remaining contractual life	7 years 4 months 24 days
Options exercisable	32,267
17.48-17.48 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 17.48
Exercise price, upper limit (in dollars per share) | $ / shares	$ 17.48
Stock options outstanding	90,000
Weighted-average remaining contractual life	8 years 4 months 24 days
Options exercisable	90,000
20.88-20.88 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 20.88
Exercise price, upper limit (in dollars per share) | $ / shares	$ 20.88
Stock options outstanding	47,187
Weighted-average remaining contractual life	8 years 1 month 6 days
Options exercisable	20,105
21.00-21.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 21
Exercise price, upper limit (in dollars per share) | $ / shares	$ 21
Stock options outstanding	20,000
Weighted-average remaining contractual life	8 years 2 months 12 days
Options exercisable	9,167
$34.65-34.65 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, lower limit (in dollars per share) | $ / shares	$ 34.65
Exercise price, upper limit (in dollars per share) | $ / shares	$ 34.65
Stock options outstanding	45,622
Weighted-average remaining contractual life	9 years 1 month 6 days
Options exercisable	0

Stock-Based Compensation Plan65

Stock-Based Compensation Plans - Restricted Stock Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Number of Units and Awards
Restricted stock units granted (shares)	593,003	508,729	1,205,200
Restricted stock units canceled (shares)	(174,094)	(157,358)	(163,689)
Weighted-Average Grant Date Fair Value (in dollars per share)
Awards other than options withheld for tax (shares)	259,107	311,368	85,661
Restricted stock units [Member]
Number of Units and Awards
Beginning balance (shares)	1,533,081	1,906,696	1,157,450
Restricted stock units granted (shares)	593,003	508,729	1,205,200
Restricted stock units released (shares)	(639,339)	(724,986)	(292,265)
Restricted stock units canceled (shares)	(174,094)	(157,358)	(163,689)
Ending balance (shares)	1,312,651	1,533,081	1,906,696
Weighted-Average Grant Date Fair Value (in dollars per share)
Beginning Balance (weighted average exercise price) (per share)	$ 10.08	$ 5.60	$ 5.38
Restricted stock units granted (weighted average exercise price) (per share)	31.96	19.99	5.57
Restricted stock units released (weighted average exercise price) (per share)	10.76	6.03	5.35
Restricted stock units canceled (weighted average exercise price) (per share)	14.16	6.50	4.31
Ending Balance (weighted average exercise price) (per share)	$ 19.09	$ 10.08	$ 5.60
Awards other than options withheld for tax (shares)	259,107	311,368	85,661

Stock-Based Compensation Plan66

Stock-Based Compensation Plans - Stock-Based Compensation Expense (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation			$ 9,383,000
Stock-based compensation		$ 13,219,000	9,383,000	$ 6,660,000
Stock-based compensation expense due to modification		0	0	700,000
Total unrecognized compensation costs		$ 19,400,000
Total unrecognized compensation costs, period of recognition		2 years 7 months
Restatement Adjustment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenue reduction	$ (700,000)
Restatement Adjustment [Member] | Adjustment Related to Fiscal Year 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenue reduction	$ (400,000)
Performance Based Stock Options and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 2,500,000	1,600,000	1,000,000
Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		205,000	833,000	0
Cost of revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		744,000	443,000	248,000
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		1,619,000	1,073,000	1,645,000
Selling and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		5,129,000	2,917,000	1,783,000
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 5,522,000	$ 4,117,000	$ 2,984,000

Stock-Based Compensation Plan67

Stock-Based Compensation Plans - Assumptions (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	4 years 9 months 18 days	4 years 4 months 24 days	4 years 9 months 18 days
Expected volatility	63.00%	43.00%	51.00%
Risk-free interest rate	1.29%	1.25%	1.02%
Expected dividend yield	0.00%	0.00%	0.00%

Stock-Based Compensation Plan68

Stock-Based Compensation Plans - Employee and Nonemployee Stock-Based Compensation (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (shares)		45,622	255,000	568,987
Awards other than options granted (shares)		593,003	508,729	1,205,200
Capitalized stock-based compensation cost		$ 0	$ 0	$ 0
Recognized stock-based compensation tax benefits		1,300,000	100,000	0
Stock-based compensation expense related to non-employee grants		400,000	600,000	500,000
Stock-based compensation			9,383,000
Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation		$ 205,000	$ 833,000	$ 0
Restatement Adjustment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenue reduction	$ (700,000)
Restatement Adjustment [Member] | Adjustment Related to Fiscal Year 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenue reduction	$ (400,000)
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (shares)		45,622	255,000	543,987
Weighted-average grant date fair value, stock options (in dollars per share)		$ 18.19	$ 6.77	$ 6.75
Aggregate intrinsic value		$ 2,800,000	$ 3,200,000	$ 6,800,000
Total fair value		$ 2,700,000	$ 4,300,000	$ 4,900,000
Employee Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards other than options granted (shares)		593,003	508,729	1,180,200
Weighted-average grant date fair value, awards other than options (in dollars per share)		$ 32.05	$ 19.99	$ 5.62
Fair value of the respective vesting dates		$ 6,400,000	$ 4,300,000	$ 1,400,000
Performance Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (shares)		64,938	40,000	40,000
Stock-based compensation		$ 2,500,000	$ 800,000	$ 200,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based and Nonemployee Services Transaction, Vesting Period			6 months	6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based and Nonemployee Services Transaction, Vesting Period			2 years	2 years

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Matching 401(k) contributions	$ 1.8	$ 1.5	$ 1.1

Income Taxes - Domestic And For

Income Taxes - Domestic And Foreign Components of Income (Loss) before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Domestic	$ 14,065	$ 1,443	$ (19,535)
Foreign	(10,733)	319	370
Income (loss) before income taxes	$ 3,332	$ 1,762	$ (19,165)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current provision:
Federal	$ 654	$ 0	$ 0
State	1,098	156	60
Foreign	183	94	61
Total current	1,935	250	121
Deferred provision (benefit):
Federal	(34,835)	0	0
State	(5,576)	0	0
State	6	(19)	19
Total deferred	(40,405)	(19)	19
Total provision for (benefit from) income taxes	$ (38,470)	$ 231	$ 140

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of The Statutory Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	5.00%	6.00%	2.00%
Non-deductible permanent difference	16.00%	22.00%	(1.00%)
Non-deductible executive compensation	51.00%	150.00%	0.00%
Change in valuation allowance	(1394.00%)	(157.00%)	(34.00%)
Research and development credits	(36.00%)	(47.00%)	(2.00%)
Stock-based compensation	11.00%	6.00%	(1.00%)
Impact of foreign operations	153.00%	(2.00%)	0.00%
Impact of foreign operations	4.00%	0.00%	0.00%
Effective tax rate	(1155.00%)	13.00%	(1.00%)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 19,829	$ 31,237
Income tax credits	5,867	4,838
Other Tax Credit	851	0
Depreciation and amortization	4,855	5,615
Accruals and reserves	7,606	4,316
Stock-based compensation	3,950	2,790
Total deferred tax assets	42,958	48,796
Valuation allowance	(2,483)	(48,730)
Net deferred tax assets	$ 40,475	$ 66

Income Taxes - Operating Loss C

Income Taxes - Operating Loss Carryforwards (Details) $ in Millions	Dec. 31, 2015USD ($)
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	$ 104.3
Unrecognized tax benefits resulting from the exercise of employee stock awards	57.2
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	96.3
Unrecognized tax benefits resulting from the exercise of employee stock awards	22.9
Research Tax Credit Carryforward [Member] | Federal [Member]
Operating Loss Carryforwards [Line Items]
Credit carryforwards	4.2
Research Tax Credit Carryforward [Member] | State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	73
Credit carryforwards	$ 4.8

Income Taxes Income Taxes - Val

Income Taxes Income Taxes - Valuation allowance (Details) - Valuation allowance of deferred tax assets [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 48,730	$ 51,003	$ 44,926
Additions	673	1,011	6,077
Deductions	(46,920)	(3,284)	0
Balance at End of Year	$ 2,483	$ 48,730	$ 51,003

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Unrecognized tax benefits increase (decrease)		$ 1,400
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning balance		1,453	$ 2,925	$ 902
Gross increase on tax positions related to the prior year		99		1,434
Gross increase on tax positions related to the current year		1,341	274	589
Gross decrease on tax positions related to the prior year			(1,746)
Ending balance	$ 2,893	2,893	$ 1,453	$ 2,925
Increase (decrease) in valuation allowance	(40,400)
Undistributed earnings of foreign subsidiaries	$ 600	$ 600

Net Income (Loss) per Share o77

Net Income (Loss) per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator
Net income (loss) (in thousands)	$ 40,606	$ 2,147	$ 1,178	$ (2,129)	$ 1,317	$ 4,782	$ 2,769	$ (7,337)	$ 41,802	$ 1,531	$ (19,305)
Denominator
Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic (shares)	39,093,825	38,881,183	38,649,873	38,383,022	37,958,395	37,630,222	37,440,537	37,215,697	38,754,643	37,563,590	36,209,051
Dilutive effect of incremental shares and share equivalents									2,041,003	3,433,382	0
Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted	40,966,744	40,860,593	41,641,660	38,383,022	41,434,178	40,926,034	40,597,275	37,215,697	40,795,646	40,996,972	36,209,051
Net income (loss) per share:
Net income (loss) per share, basic (dollars per share)	$ 1.04	$ 0.06	$ 0.03	$ (0.06)	$ 0.03	$ 0.13	$ 0.07	$ (0.20)	$ 1.08	$ 0.04	$ (0.53)
Net income (loss) per share, diluted (dollars per share)	$ 0.99	$ 0.05	$ 0.03	$ (0.06)	$ 0.03	$ 0.12	$ 0.07	$ (0.20)	$ 1.02	$ 0.04	$ (0.53)

Net Income (Loss) per Share o78

Net Income (Loss) per Share of Common Stock - Outstanding Shares of Potentially Dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (shares)	65,787	233,435	5,591,107
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (shares)	39,497	220,712	3,598,385
Restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (shares)	26,290	12,723	1,906,696
Common stock issuable pursuant to the ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (shares)	0	0	86,026

Supplemental Cash Flow Inform79

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 13	$ 0	$ 0
Cash paid for income taxes	38	285	188
Non-cash investing and financing activities:
Assets acquired under capital leases	0	(382)	0
Accounts payable and accrued liabilities related to property, plant and equipment purchases	$ 843	$ 106	$ 14

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)segmentmanagerbusiness_activity	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Segment Reporting Information [Line Items]
Number of business activities | business_activity									1
Number of segment managers held accountable for operations | manager									0
Number of reportable segments | segment									1
Revenue	$ 78,225	$ 61,202	$ 64,431	$ 51,558	$ 50,772	$ 45,670	$ 47,061	$ 30,975	$ 255,416	$ 174,478	$ 111,626
Systems Revenue [Member]
Segment Reporting Information [Line Items]
Revenue									130,698	93,015	61,359
Consumable Revenues [Member]
Segment Reporting Information [Line Items]
Revenue									124,718	81,463	50,267
North America [Member]
Segment Reporting Information [Line Items]
Revenue									193,376	134,434	89,150
United States [Member]
Segment Reporting Information [Line Items]
Revenue									180,500	125,000	83,700
International [Member]
Segment Reporting Information [Line Items]
Revenue									$ 62,040	$ 40,044	$ 22,476

Supplementary Financial Data 81

Supplementary Financial Data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Total revenue	$ 78,225	$ 61,202	$ 64,431	$ 51,558	$ 50,772	$ 45,670	$ 47,061	$ 30,975	$ 255,416	$ 174,478	$ 111,626
Gross profit	52,385	45,161	46,315	37,180	35,939	33,115	33,401	21,959	181,041	124,414	77,437
Net income (loss)	$ 40,606	$ 2,147	$ 1,178	$ (2,129)	$ 1,317	$ 4,782	$ 2,769	$ (7,337)	$ 41,802	$ 1,531	$ (19,305)
Net income (loss) per share, basic (dollars per share)	$ 1.04	$ 0.06	$ 0.03	$ (0.06)	$ 0.03	$ 0.13	$ 0.07	$ (0.20)	$ 1.08	$ 0.04	$ (0.53)
Shares used in calculation-basic (shares)	39,093,825	38,881,183	38,649,873	38,383,022	37,958,395	37,630,222	37,440,537	37,215,697	38,754,643	37,563,590	36,209,051
Net income (loss) per share, diluted (dollars per share)	$ 0.99	$ 0.05	$ 0.03	$ (0.06)	$ 0.03	$ 0.12	$ 0.07	$ (0.20)	$ 1.02	$ 0.04	$ (0.53)
Shares used in calculation-diluted (shares)	40,966,744	40,860,593	41,641,660	38,383,022	41,434,178	40,926,034	40,597,275	37,215,697	40,795,646	40,996,972	36,209,051
Change in valuation allowance	$ (40,400)